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ABSTRACT OF THE DISSERTATION
CONJUGATED POLYMERS NANOPARTICLES FOR BIOLOGICAL LABELING
AND DELIVERY
by
Eladio Mendez
Florida International University, 2015
Miami, Florida
Professor Joong Ho Moon, Major Professor
Cancer remains one of the world’s most devastating diseases, with more than 10 million
new cases every year. However, traditional treatments have proven insufficient for
successful medical management of cancer due to the chemotherapeutics’ difficulty
in achieving therapeutic concentrations at the target site, non-specific cytotoxicity to
normal tissues, and limited systemic circulation lifetime. Although, a concerted effort has
been placed in developing and successfully employing nanoparticle(NP)-based drug
delivery vehicles successfully mitigate the physiochemical and pharmacological
limitations of chemotherapeutics, work towards controlling the subcellular fate of the
carrier, and ultimately its payload, has been limited. Because efficient therapeutic action
requires drug delivery to specific organelles, the subcellular barrier remains critical
obstacle to maximize the full potential of NP-based delivery vehicles. The aim of my
dissertation work is to better understand how NP-delivery vehicles’ structural,
chemical, and physical properties affect the internalization method and subcellular
localization of the nanocarrier.

viii

In this work we explored how side-chain and backbone modifications affect the
conjugated polymer nanoparticle (CPN) toxicity and subcellular localization. We
discovered how subtle chemical modifications had profound consequences on the
polymer’s accumulation inside the cell and cellular retention. We also examined how
complexation of CPN with polysaccharides affects uptake efficiency and
subcellular localization.
This work also presents how changes to CPN backbone biodegradability can
significantly affect the subcellular localization of the material. A series of
triphenyl phosphonium-containing CPNs were synthesized and the effect of
backbone modifications have on the cellular toxicity and intracellular fate of the
material. A mitochondrial-specific polymer exhibiting time-dependent release is
reported. Finally, we present a novel polymerization technique which allows for the
controlled incorporation of electron-accepting benzothiadiazole units onto the polymer
chain. This facilitates tuning CPN emission towards red emission.
The work presented here, specifically, the effect that side-chain and structure,
polysaccharide formulation and CPN degradability have on material’s uptake
behavior, can help maximize the full potential of NP-based delivery vehicles for
improved chemotherapeutic drug delivery.
.
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CHAPTER I

INTRODUCTION TO NANOPARTICLE-BASED DRUG
DELIVERY SYSTEMS

1

1.1 Challenges in Cancer Therapy
Cancer remains one of the world’s most devastating diseases, with more than 10 million
new cases every year. However, as a result of improved understanding of tumor biology,
improved diagnostic devices and treatments, mortality rates have recently begun to
decrease.1 Current clinical therapy for cancer includes a combination of chemotherapy,
radiotherapy, and surgery, among others.2 However, these traditional treatments have
proven insufficient for successful medical management of cancer patients because of the
undesired physiochemical and pharmacological properties for the chemotherapeutics
often employed.2 These chemotherapeutics exhibit narrow therapeutic index (TI)
because of their difficulty in achieving therapeutic concentrations at the target site, nonspecific cytotoxicity to normal tissues, limited systemic circulation lifetime and problems
associated with the physical properties of the drugs, such as low in vivo solubility. At the
cellular level, non-specific cellular uptake and undesirable subcellular distributions
further reduce the chemotherapeutics’ TI.
1.2

Biological Barriers to Effective Drug Delivery

There are several biological barriers that must overcome if therapeutic concentrations of
the drug are to be effectively delivered to target tumor sites. These barriers can be
organized into three distinct levels: a physiological, cellular, and subcellular barrier.
Each poses a different challenge for effective drug delivery.
At the physiological level, most drugs will undergo rapid systemic clearance preventing
them from staying in circulation long enough to reach the tumor site. This systematic
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clearance results in the drug’s degradation in plasma, rapid mononuclear phagocyte
system (MPS) uptake, and renal filtration out of the organism. At the cellular level, the
cancer cell’s phospholipid membrane presents a major barrier to cellular entry.
Although drugs enter cells in various ways, many rely on passive transport such as
diffusion or channel proteins to facilitate crossing the cell membrane. Passive transport
limits the drug internalization once equilibrium between intracellular and extracellular
space is reached. Additionally, the presence of membrane bound drug-efflux pumps,
which actively vacuum drug molecules out of the cell, further decreases drug
internalization into the cell.3 Finally, upon internalization into the cell, the distribution of
the drug within the subcellular organelles plays a key role in the effectiveness of the
drug. For therapeutic action to take place, most drugs require them to reach specific
organelles. Depending on the entry pathways and subcellular trafficking, internalized
materials will be trafficked into different organelles, which will significantly influence
the overall efficiency of the drug.4 Successful drug delivery to the target organelle
requires all three biological barriers to be overcome which results in a high exclusivity
towards a wide variety of molecules. In recent years, two main approaches have been
adopted for chemotherapeutics to overcome these biological barriers.
One approach has focused on designing and developing new derivatives of
chemotherapeutics

exhibiting

improved

physiochemical

and

pharmacological

properties.5 The drug discovery-based approach has had limited success, as even small
modifications can often change the function and bioactivity and pharmacokinetics of the
parent drug. The other approach has focused on modifying the existing
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chemotherapeutic

agents

using

drug

delivery

technologies.6

As

a

result,

nanoparticle(NP)-based delivery systems have emerged as a promising alternative that
can overcome many of the limitations of direct drug modification and offer a platform
which can be modified for the intracellular delivery of cargos with varying charge, size,
and molecular weight.7
1.1.2

Nanoparticle-based Drug Delivery

The requirements for a NP-based drug delivery system to be successful include:
compatibility with the drug to be delivered, high drug loading efficiency, target-cell
specificity, sustained systemic circulation, and a controllable drug release profile. Because
they usually exhibit particle sizes 50-200 nm, NP-based delivery systems are often termed
“nanocarriers.” Ideally, these nanocarriers should be inexpensive, reproducibly
synthesized, and exhibit non-toxic biodegradation upon drug release. To tackle these
material needs, a number of platforms have been synthesized and explored as possible
delivery vehicles; these include naturally-derived polymers8, liposomes9, and synthetic
polymers10, among others.
Naturally-derived polymers include bio-polymers like chitosan, hyaluronic acid, cellulose,
fibrin, collagen, and gelatin.8 These polymers offer good biocompatibility that may
positively support cell adhesion and function, and most exhibit biodegradable linkages
that further lower toxicity. However, naturally derived polymers also have displayed
immunogenicity and offer decreased control over their mechanical properties,
inconsistency between batches, and high cost due to limited supply.
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Liposomes are spherical lipid vesicles consisting of a bilayered lipid membrane, which
can be prepared synthetically or from natural sources.9 These materials allow for the
surface charge to be negative, neutral, or positive depending on the lipid head group
composition, which has been shown to influence the NP stability, bio-distribution, as well
as the uptake by targeted cells.11 As a result of their biodegradability and biocompatibility
there are several liposomes and lipid-based products currently approved for clinical use in
the U.S.12. However, liposomes have exhibited particle stability issues, payload
incompatibility leading to low drug entrapment, as well as poor particle size control.
Synthetic polymers, which include polyethylene and polystyrene, polyacrylates and
polyesters, are synthetically-made polymers offering wide variety of variations to main
and side-chains.10 They offer good biocompatibility, inexpensive and reproducible
synthetic methods compatible with large scale production, controllable biodegradation,
and improved drug release profiles. Additionally, incorporation of various functional
groups can be synthesized to improve compatibility with the specific drugs to be
delivered. Because of these desirable properties, this class of materials has been
extensively explored to encapsulate drugs in colloidal systems.
1.2.1. Pharmacokinetics and Passive Targeting
To achieve more efficient tumor targeting, drugs must overcome the physiological level
barrier caused by the rapid drug clearance via MPS uptake and renal filtration. A
simple, widely used technique involves coating therapeutics with a layer of polyethylene
glycol (PEG), a synthetic hydrophilic polymer that has been shown to retard MPS
recognition and increase circulation time by forming a hydration layer that inhibits
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hydrophobic and electrostatic interactions with plasma proteins.13 Incorporation of PEG
to drugs results in a pseudo-delivery vehicle layer which results in improved drug
solubility, extended circulation life, increased drug stability, and enhanced protection
from proteolytic degradation. These pharmacokinetic changes result in more constant
and sustained plasma concentrations, which lead to increases in clinical effectiveness
when the desired effects are concentration-dependent. Incorporation of other polymers
such

as

N-(2-hydroxypropyl)meth-acrylamide

(HPMA)

have

shown

similar

enhancements to the circulation time.14
Nanocarriers exhibit similar pharmacokinetic enhancements by passively targeting
cancer tumors in vivo. Passive targeting is achieved by the enhanced permeability and
retention (EPR) effect that arises from the increased permeability of tumor blood
vessels, a characteristic of rapid and defective angiogenesis. Enhanced retention in the
interstitial fluid surrounding the tumor is achieved due to dysfunctional lymphatic
drainage often seen in tumor tissues. The EPR effect enables NPs to accumulate in
tumor tissue much more readily than they do in healthy tissues, which results in lower
toxicity to normal tissues. NPs with sizes of up to 400 nm have been reported to exhibit
EPR, however, particles with diameters of less than 200 nm have been reported to be
more effective.15 Because EPR relies on the increased permeability of tumor blood
vessels, passive tumor accumulation is severely diminished in poorly vascularized
tumors.
Although the intrinsic EPR effect exhibited by NP-based delivery is an elegant solution
to the physiological barrier of drug delivery, its effect on the cellular and subcellular
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barriers remaain limited. The
T EPR efffect only faacilitates druug escape frrom plasma into
th
he interstitial fluid surrou
unding the tumor,
t
resultting in non-uuniform drugg profusion into
th
he cell, and ultimately, an
a inability to
t achieve thherapeutic cconcentrationns inside canncer
ceells.

Figure
F
1.1. Schematic
S
illusstration of the enhanced perrmeation and retention (EPR) effect in solid
tumors.
t
A ) Leaky vasculature cause enhanced
e
perm
meation of nannoparticles intoo tumor tissuees. B)
also experien
Nanoparticles
N
nce enhanced retention
r
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tissues.
t
This reesults in passiv
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1.2.2. Active Targeting
g
At
A the cellulaar level, the cancer
c
cell membrane
m
prresents a maajor barrier tto cellular enntry,
ab
ble to exclu
ude large varriety of larg
ge polar mollecules. Unliike small m
molecules, whhich
passively difffuse into th
he cell, NP
Ps are mainnly internalizzed via acttive endocyttotic
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pathways. Endocytosis is an energy-dependent process by which cells internalize a
variety of macromolecules via membranous vesicles.16 Upon interaction with the cell
membrane, NPs are mainly internalized via adsorptive or receptor-mediated
endocytosis. In adsorptive endocytosis, molecules non-specifically interact with generic
complementary binding sites such as negatively charged heparin sulfate proteoglycans
and hydrophobic membrane lipids. In receptor-mediated endocytosis, ligands bind to
receptors on the cell surface and are internalized by endosomal vesicles. By
incorporating ligand moieties onto the nanocarrier, various researchers have made a
concerted effort to enhance the cellular uptake of NPs.17 The active targeting of cellular
membrane receptors which are up regulated or uniquely expressed cancer cells ensures
that the nanocarriers are preferentially localized and internalized into cancer tissues.
Early attempts towards active targeting encompassed combining the unique targeting
capabilities of monoclonal antibodies with cancer drugs. However, as a consequence of
the large size of antibodies, simple incorporation often results in poor size control and
increased immune response.18 These limitations led to the emergence of alternative
targeting ligands such as fragment antigen-binding (Fab) antibodies and growth factors
that target overexpressed receptors in cancer cells.19 Additionally, numerous studies
have reported covalent attachment of targeting ligands for nutrients whose receptors are
overexpressed, such as peptides and carbohydrates, to NP surfaces. 17 The small physical
dimension of these ligands enables for NP incorporation in high density without
compromising the particle’s circulation time or eliciting an immune response.18 High
ligand density results in improved internalization as the efficiency of receptor-mediated
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en
ndocytosis is dependentt on both thee strength off the ligand--receptor inteeraction andd the
nu
umber of in
nteracting receptor-ligan
nd complexees.20 Additioonally, new dual and m
multiliigand approaaches exhibitting synergistic targetingg enhancem
ment to the taarget tumor ccells
have been rep
ported.21

Fiigure 1.2. Schem
matic illustration of NP endo
ocytosis to crosss the membranne barrier for ccellular entry. A
A) The

drrug-loaded ligaand-containing
g NP binds to receptor. B) T
The receptor-N
NP complex is internalized innto the
ceell via an endo
ocytosis pathwaay. C) Upon in
nternalization, the therapeutic agent must eescape the endoosome
to
o reach its targeet destination.

1.3.

Subceellular Barrrier

In
n order for therapeutic
t
action
a
to tak
ke place, moost drugs reqquire them tto reach speccific
orrganelles su
uch as thee nucleus, Golgi appaaratus, mitoochondria, oor endoplassmic
reeticulum. However,
H
beecause of th
heir large siize and hyddrophilic natture, NPs ooften
un
ndergo endo
ocytosis path
hways that result in intraacellular traffficking via endosomes that
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undergo rapid maturation to lysosomes.22,23 Nanoparticle accumulations in lysosomal
compartments often lead to enzymatic degradation and/or recycling back to the cell
surface, even for systems that take advantage of active targeting by covalent attachment
of targeting ligands as they undergo receptor-mediated endocytosis. Therefore,
endocytosis poses a major barrier for drug delivery as therapeutic compounds that are
transported via these acidic organelles may be inactivated and significantly reduced in
concentration before reaching their site of action.
To overcome lysosomal degradation and low delivery efficiency because of recycling
out of the cell, a variety of nanocarriers have been developed that respond to the acidic
environment of the lysosome.24,

25

These pH-responsive carriers aim to increase

intracellular drug bioavailability by facilitating release out of the endosome or
enhancing drug transit to the cytoplasm. Synthesis of polymer-drug conjugates
containing pH-sensitive linkages have been shown to release drugs which then diffuse
out of the endosome. Unfortunately, reaching appropriate therapeutic concentrations at
the appropriate subcellular target site can be difficult because of low drug-loading
capacities. Several cationic polymers have been reported to incorporate “proton
sponges” that can facilitate endosomal escape.25 These nanocarriers work by
incorporating functional groups that can effectively buffer the acidic endosomal
environment, prompting the osmotic swelling, rupture out of the vesicle and into the
cytoplasm. Similarly, it has been shown that high molecular weight (MW) branched
amine-containing polymers can damage and destabilize the endosomal membrane.26
Incorporation of charged pendant, such as carboxylic acids, has been demonstrated to
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cause NP swelling upon acidification which can rupture the endosome to initiate the
endosomal escape.25 Finally, fusogenic peptides have been incorporated for the
endosomal escape of several drug delivery systems.27 These peptides assume coil-like
structures at neutral pH, and that upon acidification in the endosome, result in a
conformational change that facilitates penetration out of the endosomal membrane.
An innovative approach has been to forgo endocytosis entirely via incorporation of cellpenetrating peptides (CPPs) that enable transport into the cytosol.28 Cell-penetrating
peptides avoid endosomal internalization by targeting protein transduction domains for
the transport directly into the cytosol. Incorporation of CPPs onto various
macromolecules and nanocarriers to assist internalization into mammalian cells.28 The
promising strategy of using CPPs remains limited by its cost-effectiveness and difficult
optimization as the mechanism by which these peptides gain direct access to the cell
cytoplasm remains unclear, due to mechanistic differences from peptide to peptide.
Although these strategies have been developed and employed to varying degrees of
success, it becomes clear that to improve drug efficacy, the nanocarrier should not only
facilitate successful delivery into specific cell types or tissues, but direct the drug to its
appropriate intracellular destination.
1.3.1. Nanocarrier Subcellular Localization
As a result of the significant amount of research has been devoted to addressing the
physiological and cellular barriers, NPs have emerged as a safer and more effective drug
delivery option when compared to small molecule chemotherapy. Several nanocarrier
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platforms have been reported exhibiting long systemic circulation lifetime, passive and
active targeting ability, cellular internalization through endocytosis, and novel strategies
designed to facilitate endosomal escape and avoid lysosomal degradation.24-26 However,
work towards controlling the subcellular fate of the carrier, and ultimately its payload,
has been limited. Because efficient therapeutic action requires drug require delivery to
specific organelles, this subcellular barrier remains critical obstacle to maximize the full
potential of NP-based delivery vehicles.
1.3.2. Biological Factors Affecting Subcellular Localization
The main mechanisms for the endocytotic internalization of nanocarriers are
macropinocytosis, Clathrin-mediated endocytosis, and Caveolae-mediated endocytosis. 23
Depending on the mechanism, the materials are either sorted towards different organelles
or recycled out to the extracellular fluid, making the method of internalization the most
important factor that affecting the subcellular fate of a nanocarrier. 23, 30
Macropinocytosis (MPC) is an actin-driven endocytosis process that results in the
formation of macropinosomes, vesicles of irregular size and shape containing no protein
coat.31 Macropinosomes result from the activation of tyrosine kinase receptors that trigger
actin-driven invagination of the plasma membrane. In human cells, macropinosomes
rarely fuses with lysosomes, instead behaving as a distinct vesicle population.30 Although
contents are often recycled out of the cell, much of the internalized payload can escape
from macropinosomes and into the cytosol because of the inherently “leaky” nature of
macropinosomes. Active targeting of MPC can be achieved via incorporation of tyrosine

12

kinases like epidermal growth factor and platelet-derived growth factor onto the
nanocarrier.
Clathrin-mediated endocytosis (CME) is a highly regulated and well-studied energydependent receptor-mediated process.30 Transferrin and low-density lipoprotein (LDL)
receptors will undergo CME upon binding with the appropriate ligand. Once bound, the
receptor-ligand complex is opsonized in clathrin-coated vesicles, forming vesicles
ranging in size from 100 to 150 nm in diameter. As the vesicle is internalized, the
clathrin coat depolymerizes, forming early endosomes. Within these endosomes, the
contents are sorted to their appropriate cellular destinations, such as lysosomes, the
Golgi apparatus, the nucleus, or the cell surface.30 Understanding how to efficiently
manipulate the endosomal sorting remains limited, however, GTPases and Rab proteins
are known to control this process. Active targeting of CME can be achieved via
incorporation of pendant transferrin ligands.
Finally, Caveolae-Mediated Endocytosis (CvME) is an energy-dependent receptormediated process which results in a non-degradative route of internalization.30-32
Caveolae are hydrophobic membrane microdomains that are rich in cholesterol and
glycosphingolipids-binding receptors. Upon binding with the appropriate ligand, the
receptor-ligand complex is internalized via caveosomes, flask-shaped invaginations of the
plasma membrane, ranging in size from 50 to 60 nm in diameter and as large as 500 nm
long, and mediated by membrane-bound caveolin proteins. Once internalized, the
contents are sorted within the caveosomes for delivery to the endoplasmic reticulum or
Golgi apparatus. Active targeting of CvME can be achieved via incorporation of
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cholesterol and glycosphingolipids-rich compounds, which have been shown to be
preferentially internalized via this endocytotic pathway.
1.3.3. Control of Subcellular Localization in NP-delivery Systems
A variety of approaches been reported for NP-based delivery systems which overcome
the subcellular barrier presented by the cellular membrane, including cell penetrating
peptides, targeting ligands, pH dependent nanocarriers, as well as targeting specific
endocytosis mechanisms, among others. Unfortunately, most of these methods direct the
payload towards the cytosol as the target site of delivery. Targeting organelles such as the
mitochondria, pose a further challenge as these organelles necessitate penetration of the
organelle membranes for effective drug delivery.31 Mitochondrial dysfunction is
responsible for a variety of human disorders, ranging from neurodegenerative diseases,
obesity, diabetes, and cancer. Because mitochondria play a key role in cell death
pathways, targeted drug delivery to this organelle could play a crucial role for future
cancer treatments.
Although various targeting moieties exist that effectively target these organelles,
incorporation of these ligands to macromolecules (e.g. nanocarriers) do not always
afford organelle-specific targeting. For example, triphenylphosphonium (TPP)
conjugates readily target the mitochondria because of its amphilicity and cationic
nature.31 Triphenylphosphonium conjugates have been reported to deliver smallmolecular weight antioxidants and nucleic acid oligomers. However, successful
mitochondrial localization was only achieved when TPP was incorporated into HPMA
with an average molecular weight below 5 kDa. Higher molecular HPMA copolymers
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did not show mitochondrial localization even that after polymer microinjection into the
cytosol. Other mitochondrial-targeting materials include incorporation of fusogenic
peptides, such as Mito-8, to quantum dots to afford mitochondria-specificity. Finally,
materials like dequalinium (DQA), which can form liposome-like aggregates, have been
reported to exhibit plasmid DNA (pDNA) encapsulation, cellular internalization, and
pDNA delivery.34 However, DQA does not exhibit improved pharmacokinetics, passive
or active targeting towards cancer cells.
1.4.

Conjugated Polymer Nanoparticles

Conjugated polymer nanoparticles (CPNs) and conjugated polyelectrolytes (CPEs) are
emerging fluorescent synthetic polymers that have been employed towards cellular
labelling,
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sensing,36 and delivery37 of biological substances. They are prepared from

semiconducting conjugated polymers (CP), fluorescent polymers that have been heavily
utilized in the fields of electronics for light-emitting diodes (LEDs), photonic devices
components, solar cells, and field-effect transistors (FETs). 38
Various developments have catalyzed the rapid increase in using CPNs for biological
applications. Several strategies have been developed to introduce water-solubility and
overcome the inherent hydrophobicity of the material.39 Well established synthetic
methods allow for facile modifications of π-electron conjugated backbones and sidechains to tune fluorescent emission, facilitate controllable biodegradation, incorporate
targeting units, and improve drug release profiles. Finally, owing to their fluorescent
nature, CPNs are a unique delivery platform that can facilitate understanding of how
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chemical structures affect the uptake behavior, bio-distribution and subcellular
localization of these polymeric vehicles.

Figure 1.3. Common examples of conjugated polymers

1.4.1. Characterization of Endocytosis Mechanisms and Subcellular Localization
Most methods to study intracellular trafficking of nanomaterials involve either
inhibition of specific endocytosis mechanisms using pharmacological inhibitors or
colocalization of nanomaterials with specific endocytosis markers and structures.30
Various pharmacological inhibitors can be commercially purchased to specifically
inhibit certain endocytotic pathways. Clathirin-mediated endocytosis can be
distinguished by inhibition under a potassium depletion condition or by treating cells
with a pharmacological inhibitor such as chlorpromazine, which specifically inhibits the
pit formation by dissociating clathrin lattices. Filipin, nystatin, and methyl-βcyclodextrin specifically bind, sequester, or deplete cholesterol, which is involved in the
CvME. As a tyrosine kinase inhibitor, genistein also blocks CvME.23 Cytochalasin D
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causes actin de-polymerization in the cytoskeleton, resulting in involvement in both the
CvME and macropinocytosis.23 Bulk amounts of macromolecules can be taken up by
cells via macropinocytosis, which involves cell surface ruffling. Since actin
cytoskeletons affect membrane ruffling, drugs (e.g., amiloride and its derivatives) that
disrupt the function of the actin cytoskeleton can inhibit macropinocytosis.23
Phosphatidyl inositol-3-phosphate inhibitor, LY294002 is often used for testing
macropinocytosis. Because treatments often show cell type-dependent nonspecific
toxicity, baseline toxicity must first be assessed. The change in nanocarrier uptake upon
the inhibition of specific endocytotic mechanisms can be measured using flow
cytometry. Flow cytometry is an instrumental technology that can measure multiple
physical characteristics of cells, such as fluorescence and scattered light, as they flow in
a fluid stream through a beam of light. The relative fluorescence intensity per cell can be
measured to determine nanocarrier uptake.
Subcellular localization of nanocarriers can be monitored by fluorescent microscopic
imaging.31 By taking advantage of CPN’s fluorescent nature, the materials can be
incubated with live cells and can then be co-stained with standard fluorescent dyes
which are internalized to specific organelles. For instance, treating cells with pHRhodo
Dextran (10kDa) and BODIPY-TR C5-ceramide-BSA complex will label acidic
organelles (i.e., endosomes and lysosomes) and Golgi apparatus, respectively.
Quantitative co-localization information can then be obtained from the micrographs
using the Pearson's Correlation Coefficient (PCC) method. The PCC method gauges the
level of overlap by measuring the pixel-by-pixel covariance in the signals of two
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images. Because the PCC method uses normalized signals by subtracting the mean
intensity from each pixel's intensity value, PCC is independent of signal levels (i.e.
probe brightness) and signal offset (i.e. background). PCC values of 0 and 1 correspond
to uncorrelated and perfectly linear correlated images, respectively.
1.4.2. CPN Characterization
Internalization mechanism and subcellular localization are influenced by a variety of the
CPN’s physical properties, such as molecular weight, particle size, and zeta potential.33
Therefore, proper characterization of a CPN’s physical properties is paramount to
accurately correlate the nanocarrier’s physiochemical properties with the endocytosis
mechanism and subcellular localization.
Physical characteristics often measured for the CPN include molecular weight,
polydispersity, and particle size. Polymer molecular weight is typically measured by gel
permeation chromatography (GPC), a chromatographic technique which separates a
mixture based on size. Molecular weight and polydispersity index (PDI) can be obtained
relative to standard samples, typically polystyrene. Particle size can be measured using
light scattering techniques such as dynamic light scattering (DLS) or nanoparticle
tracking analysis (NTA). Both measure fluctuations in scattered light which is a function
of the Brownian motion experienced by the particle. The Brownian motion is related to
the hydrodynamic radius through the Stokes-Einstein equation.
Chemical characterization of the polymers can be measured using spectroscopic
techniques such nuclear magnetic resonance (NMR) spectroscopy, and various
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absorption and fluorescence spectroscopic techniques. Proper characterization ensures
that correlation of chemical moieties, and CPN chemical structure can be properly
correlated to endocytosis mechanism and subcellular localization. The chemical
structure of a polymer sample can be ascertained by NMR spectroscopy. Changes of
magnetic moment of magnetically active nuclei of hydrogen/protons (1H) and carbon
(13C) are typically obtained. NMR spectra give quantitative information about the
relative proportion of each proton in the polymer chain, allowing the average frequency
of each monomer in the polymer chain. The presence of numerous functional groups in
a polymer sample can be detected using Fourier transform infrared spectroscopy (FTIR).
The photophysical properties of conjugated polymers are measured typically using UVVisible absorption spectroscopy absorption and fluorescence spectroscopy.
1.5.

Scope and Organization

Nanoparticles are emerging as a safer and more effective drug delivery option as
compared to small molecule chemotherapy. Delivery of NP vehicles exhibit numerous
favorable features such as long systemic circulation lifetime, targeting ability, and
cellular internalization through endocytosis. However, work towards controlling the
subcellular fate of the carrier, and ultimately its payload, has been limited. Because
efficient therapeutic action requires drug require delivery to specific organelles, the
subcellular barrier remains critical obstacle to maximize the full potential of NP-based
delivery vehicles. The aim of my dissertation work is to better understand how CPN
structural, chemical, and physical changes affect the internalization method and
subcellular localization of the nanocarrier.
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Understanding how the chemical interactions between CPN and the cellular membrane
affect the subcellular localization and toxicity is paramount to improving overall
labelling and delivery efficiency. Chapter 2 details how side-chain and backbone
modifications affect the CPN toxicity and subcellular localization. Four model polymers
were synthesized containing differing side-chain and backbone structures, but exhibiting
similar physical properties (size, charge density). These subtle chemical modifications
had profound effects on the polymer accumulation inside the cell and cellular retention.
We demonstrate how CPN toxicity and subcellular localization can be tuned by
modifying physicochemical properties.
Chapter 3 details how complexation of CPN with polysaccharides affects uptake
efficiency and subcellular localization. The effect of siRNA complexation is also
explored. Interestingly, upon complexation with polysaccharides subcellular localization
does not change, and cellular uptake decreases. Upon siRNA complexation, cellular
uptake increases. Therefore, we report how CPN uptake efficiency and subcellular
localization is affected upon complexation with polysaccharides and nucleic acids.
Chapter 4 details how changes to CPN backbone structure can significantly affect the
subcellular localization of the material. A series of triphenyl phosphonium-containing
CPNs were synthesized and the effect of backbone modifications have on the cellular
toxicity and intracellular fate of the material were measured. A mitochondrial-specific
polymer exhibiting time-dependent release is reported.
Finally, chapter 5 details a novel polymerization technique which allows for the
controlled incorporation of electron-accepting benzothiadiazole units onto the polymer
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chain. This facilitates tuning CPN emission towards red emission which is highly
desirable, as the sensitivity of any in vivo measurements and optical imaging is
significantly enhanced due to minimal autofluorescence from biological tissues at this
range. Additionally, this polymer may exhibit different cellular behaviors as the subtle
chemical changes influence the entry and localizations.
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2.1.

Abstract

The subcellular localizations and toxicity of conjugated polymer nanoparticles (CPNs)
are dependent on the chemical structure of the side chain and backbone structures.
Amine- containing CPNs exhibit high Golgi localization with no toxicity. Incorporation
of short ethylene oxide and tertiary amine side chains contributes to decreased Golgi
localization and increased toxicity, respectively.
2.2.

Introduction

Semiconducting

conjugated

polymer

nanoparticles

(CPNs)

and

conjugated

polyelectrolytes (CPEs) are emerging fluorescent biomaterials for cellular labelling,1
sensing,2 therapeutic,3 and delivery4 of biological substances. Conjugated Polymers’
(CPs) excellent photophysical properties including high molar absorptivity, quantum
yield, and energy transfer efficiency make them suitable for the various biological
applications.5 Well established synthetic methods also allow facile modifications of both
π-electron conjugated backbones and side chains with various sensing or targeting units.
By treating non-aqueous soluble CPs under various particle formation conditions, nontoxic soft nanoparticles have been fabricated and used for cellular labelling and nucleic
acid delivery.6
Understanding cellular interactions and entry pathways of CPNs is paramount to
improving overall labelling and delivery efficiency. Depending on the entry pathways,
the materials and its payloads (i.e., drugs or genes) will be trafficked into different
organelles, which will significantly influence the overall efficiency.7 For example,
carriers entrapped in endosomes or lysosomes trafficked via a certain type of endocytosis
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will experience recycling of the contents back to the cell surface and degradation
processes in acidic lysosomes, lowering overall labelling and delivery efficiency.8
Meanwhile, exogenous materials trafficked by non-destructive organelles such as
caveosomes to Golgi apparatus (i.e., caveolae-mediated endocytosis) have high
intracellular retention.9 Delivery via macropinocytosis also can avoid lysosomal
degradation routes because macropinosomes do not fuse with the lysosomes, and the
membranes of macropinosomes are highly leaky.10 Therefore, systematic investigation to
understand and modulate the cellular interaction and pathways will have significant
impact on designing efficient labelling and delivery vehicles.
Previously, we demonstrated that CPNs fabricated by treating a CP containing both short
ethylene oxide (EO) and primary amine (e.g., P1, Figure 1) with organic acids followed
by dialysis exhibit efficient cellular labelling and delivery of small interfering RNA
without toxic effects.4a,b

Mechanistic studies further indicate that CPNs use both

Figure 2.1. Chemical structures of amine-containing CPs. Poly(p-phenyleneethynylenes) (PPEs) with
different side chains (P1-P3) and poly(p-phenylenebutadiynylene) (PPB) containing a small amount of
flexible unit in the backbone (P4) were synthesized and compared for cellular behaviours.
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energy-dependent and independent entry pathways. Among the energy dependent
pathways, CPNs enter cancer cells via caveolae-mediated endocytosis as one of entry
pathways.11 It is not clear why the CPNs use the specific entry pathway; however, the
positive charges and hydrophobicity of CPNs play important roles for interaction with
various serum proteins and the cell membranes, which will significantly influence the
subsequent cellular uptake.12 It is also known that materials having high surface-tovolume ratios exhibit size, shape, and functional group-dependent cellular interactions
and subsequent entry.13
Based on these results and observations, we hypothesized that chemical modifications in
the side chains of CPs will change the subcellular localizations of CPNs, because the
modulated surface properties will influence the cellular interactions of CPNs and their
subsequent entry into cells.
2.3.

Results and Discussion

To test the hypothesis, we synthesized four CPNs with different side chain (P1-3) and
backbone structures (P4) (Figure 1). Since the cellular interactions and entry processes
of nanomaterials are collectively influenced by the physicochemical properties, it is
important to keep other physicochemical properties constant when a specific parameter is
tested. Because of the particle formation mechanism (i.e., molecular weight independent
phase inverse precipitation driven by aqueous insolubility of CPs),14 the shapes and
hydrodynamic radii of CPNs are relatively constant.15 CPN-2 was designed and
synthesized to check the EO side chain effects on the toxicity and localization by
removing the EO unit from the repeating unit of CPN-1. CPN-3 was synthesized to
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Toxicity and Subcellular Localization
To test how the side chain structure influences cellular toxicity, CPNs were incubated
with human cervical carcinoma cells (HeLa) overnight at various concentrations. Zeta
potentials of CPNs had no direct correlation to the toxicity, but the chemical structure
(i.e., type and density of amine) of the side chains was related to the cellular toxicity. As
shown in Figure 2, CPN-3 containing the highest amine density, including tertiary
amines, exhibited substantial toxicity starting from 10 µM, while no cell viability
inhibition was observed up to 40 µM from the primary amine containing CPNs, whether
they contain EO side chains or flexible backbones (i.e., CPN-1, -2, and -4). Compared to
CPN-2, which contains the same amount of primary amines per repeating unit as CPN-3,
toxicity of CPN-3 can be attributed to both increased amine density and the high
buffering capacity of tertiary amines. Membrane disruption properties of synthetic
carriers

Figure 2.2. Cellular toxicity of amine-containing CPNs measured by cell
viability inhibition at various concentrations
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containing tertiary amines have been used to increase payload escape from the
endosomes or lysosomes; however, these classes of materials often cause toxicity
issues.17
Subcellular localization of CPNs was monitored by fluorescent microscopic imaging.
Overnight treatment of HeLa cells with CPNs (green) were co-stained with pHRhodo
Dextran (10kDa) (red) and BODIPY-TR C5-ceramide-BSA complex (red) for labelling
acidic organelles (i.e., endosomes and lysosomes) and Golgi apparatus, respectively
(Figure 3a and ESI). CPNs were mainly found at the perinuclear regions (punctuated
green dots) and exhibited overlaps with both pHRhodo and BODIPY. Co-localization
patterns with the Golgi were clearly distinguishable among CPNs having different side
chain or backbone structures (Figure 3a), while overlapping patterns with pHRhodo were
relatively uniform. CPN-2 and CPN-4, which only contain primary amine side chains,
exhibit high Golgi localizations (Figure 3a), while CPN-1 and CPN-3, which contain
both EO and amine side chains, exhibit a relatively low Golgi overlaps.
To obtain quantitative co-localization information, all images were further analysed using
the Pearson's Correlation Coefficient (PCC) method. The PCC method gauges the level
of overlap by measuring the pixel-by-pixel covariance in the signals of two images.
Because the PCC method uses normalized signals by subtracting the mean intensity from
each pixel's intensity value, PCC is independent of signal levels (probe brightness) and
signal offset (background).18 PCC values of 0 and 1 correspond to uncorrelated and
perfectly linear correlated images, respectively. Instead of picking small, subjective
regions of interest within an image, three independent images of an entire cell were
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mine side chaains. In addiition, CPNs fabricated w
with a
seemi-flexible CP exhibiteed the highesst Golgi locaalization. Onne-way ANO
OVA followeed by
th
he Tukey meeans separattion method confirmed tthat Golgi cco-localizatioon of CPN-22 and
CPN-4
C
was statistically
y significantt (p<0.003) from CPN
N-1 and -3.. The Golggi colo
ocalization between
b
CPN
N-2 and CPN
N-4 was alsoo statisticallyy significantt (p<0.05).
Additionally,
A
all CPNs exhibited
e
sig
gnificant latee endosome//lysosome colocalizationn. As
sh
hown in Fig
gure 4, averrage late end
dosome/lyso some PCC vvalues were not significcantly
different betw
ween CPNs, regardless of
o side chainn and backbbone structuures. This maay be
he result of adsorptive
a
en
ndocytosis, in which thee polymers nnon-specificcally interactt with
th
generic com
mplementary binding siites such aas negativelly charged heparin suulfate
prroteoglycanss and hydrop
phobic mem
mbrane lipids.

Figure 2.4.
2 Quantitativ
ve analysis of co-localization
c
using the PCC
C algorithm. Coo-localization
witth late endosom
me/lysosome diid not show siggnificant differrence regardlesss of the
side chain
c
and backb
bone structuress. The error baar represents ±sstandard deviattion (n=3).
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CPN Accumulation and Retention
The different CPN organelle trafficking is expected to significantly influence the
polymer’s accumulation intracellular retention within the cell. Because all CPNs
exhibited entrapment in late endosomes/lysosomes, they will experience recycling back
to the cell surface and degradation processes in acidic lysosomes. However, those
polymers exhibiting significant traffic to the Golgi apparatus (i.e. CPN-2 and CPN-4)
should exhibit increased cellular retention. To measure CPN accumulation, cellular
uptake was measured using flow cytometry after 2 hours and overnight (18 hours)
treatment with CPN. To measure CPN retention within the cell, cellular uptake was
measured by treating cells with the CPN for 2 hours, exchanging media, and allowing
HeLa cells to incubate overnight (16 hours). Any remaining fluorescent signal from the
CPN within the cell was measured. Cellular uptake comparison between CPNs was made
possible by normalizing the mean fluorescence measurements measured by flow
cytometer with the CPN quantum yield. It is not expected that CPNs exhibit significant
QY changes upon cellular internalization.
For all treatment times tested, CPN-4 and CPN-1 exhibited the highest and lowest
uptake, respectively (Figure 2.5). After 2 hours of treatment, CPN-2 and CPN-4
exhibited a 4-fold and 8-fold enhancement to cellular uptake over CPN-1, respectively.
After overnight treatment, CPN-2 and CPN-4 exhibited a 6-fold and 12-fold
enhancement to cellular uptake over CPN-1, respectively. Additionally, CPN-1 did not
show any significant difference in uptake between the 2 hour and overnight treatments. In
contrast, when comparing 2 hour and overnight treatments, CPN-2 and CPN-4 exhibited
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Figure 2.5. Cellular uptake
u
of CPN--1, CPN-2 andd CPN-4 measuured using flow
w cytometry.
Fluorrescence signaal was normalizzed using the C
CPN’s quantum
m yield resultinng relative
uptakee. The error baar represents ±sstandard deviattion (n=3).

1
uptakee increase, respectively.
r
The improvved uptake aand accumullation
a 158% and 170%
of CPN-2 an
nd CPN-4 prrovide strong
g evidence ffor the enhaanced internaalization thaat can
be achieved by
b controllin
ng the CPN’ss subcellularr localizationn.
The
T effect off subcellularr localization
n on the CP
PN’s cellularr retention w
was measureed by
co
omparing th
he mean fluo
orescence measured
m
by treating cellls with the C
CPN for 2 hhours,
an
nd those cellls that were treated for 2 hours and aallowed to inncubate overrnight (16 hoours).
After
A
normallizing the flluorescence signals usinng the CPN
N’s QY, all materials ttested
demonstrated
d decreased fluorescencce signal affter incubatting overnigght (Figure 2.5).
CPN-1
C
exhib
bited the hiighest clearaance, with only 40% oof the origiinal fluoresccence
in
ntensity rem
maining afterr overnight incubation.
i
CPN-2 and CPN-4 exhhibited decreeased
cllearance, ex
xhibiting 77%
% and 79% of the origiinal fluoresccence intenssity, respectiively.
Although
A
all polymers ex
xhibited diffeerent cellulaar uptake afteer 2 hours, it should be nnoted
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that even after overnight incubation CPN-2 and CPN-4 exhibited higher fluorescence
signal than even CPN-1 after overnight treatment.

2.4.

Conclusion

In conclusion, we demonstrated that CPNs are promising biomaterials with tunable
physicochemical properties. The side chain and backbone structures of CPNs are closely
related to toxicity and subcellular localization. Therefore, cellular interaction and cellular
entry pathways of CPNs can be fine-tuned to improve labelling and delivery efficiency.
The non-destructive delivery pathway and subcellular location of CPN-2 and CPN-4
afforded biocompatible materials exhibiting remarkable internalization, accumulation and
cellular retention. Combining their excellent intrinsic fluorescent natures, tunable
physicochemical properties and the related biophysical properties, CPNs make excellent
biomaterials to better understand the structure-function between nanocarrier and delivery
efficiency. The concept we demonstrated here will lead to the development of novel
multifunctional materials for labelling, sensing, and delivery.
2.5.

Outlook

Since the publication of this work in Macromolecules, a preliminary study of the
endocytosis pathway of each CPN was performed. Using pharmacological inhibitors, it
was observed that the main endocytotic pathway for EO and primary amine-containing
CPN-1 is via CvME, and secondarily via CME. For the primary amine-containing CPN2, the reverse result was observed, with a primary entry mechanism using CME and
secondarily via CvME. Branched amine-containing CPN-3 exhibited MPC as its primary
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endocytosis pathway, with CvME its secondary mechanism. Finally, the semi-flexible
backbone-containing CPN-4 exhibited almost exclusive MPC uptake, with very weak
secondary internalization via CvME uptake.
Interestingly, CPN-2 and CPN-4, both of the high Golgi co-localizing materials presented
in this chapter exhibited very different internalization mechanisms. This preliminary
endocytosis pathway confirmed CPN-2’s CvME, which we hypothesized would be the
internalization pathway due to the high Golgi uptake. However, CPN-4 exhibtied very
little CvME uptake, instead showing almost exclusive MPC mechanism. In chapter 4, a
triphenyl phosphonium-containing CPN is presented exhibiting polymeric cellular
internalization and degradation into conjugated polymer oligomer endosomal escape. We
cautiously hypothesize a similar mechanism for CPN-4, whereby the resulting aminecontaining conjugated oligomers are trafficked to the Golgi apparatus.
Further studies on polymers using CPNs presented here have revealed the unique ability
for semi-flexible linker containing-CPNs (i.e. CPN-4) to undergo self-assembly
reorganization into core-shell nanoparticles upon polyanion complexation. This ordered
aggregation allowed for the fabrication of unique CPNs for glycosaminoglycan
detection.19 In conclusion, the concept presented here has and will continue to facilitate
development of novel multifunctional materials for labelling, sensing, and delivery.
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Experimental Section
2.6.1. General
Chemicals, including solvents, were purchased from Fisher Scientific and used as
received. Deuterated solvents were purchased from Cambridge Isotope Laboratories
(Cambridge,MA). UV−vis spectra were recorded using a Varian Cary 50 Bio
spectrophotometer.

Fluorescence

spectra

were

obtained

using

a

FluoroLog-3

Spectrofluorometer (Jobin Yvon/ Horiba). 9,10-diphenylanthracene (QY = 1.0) in
cyclohexane was used as a fluorescence standard for QY determination. Hydrodynamic
radii and Zera potentials were determined by the dynamic light scattering technique using
a Zetasizer nano−ZS (Zen 3600, Malvern Instruments Ltd. , Worcestershire, United
Kingdom).

Disposable

capillary

cell

(DTS1061,

Malvern

Instruments

Ltd.,

Worcestershire, United Kingdom) used for zeta potential measurements. Low volume
disposable cuvettes (ZEN0040, Malvern Instruments Ltd., Worcestershire, United
Kingdom) used for DLS analysis. The average molecular weight (Mn) and polydispersity
index (PDI = Mw/Mn) of the polymers were determined by gel permeation
chromatography (GPC) against polystyrene standards using a Shimadzu high
performance liquid chromatography (HPLC) system fitted with PLgel 5 μm MIXED-D
columns and SPD-20A ultraviolet− visible (UV−vis) detector. Nuclear magnetic
resonance (NMR) spectra were recorded on a 400 MHz and 600 MHz Avance Bruker
NMR spectrometer. The 600 MHz NMR spectrometer is equipped with a gradient system
capable of producing magnetic field pulse gradients in the z-direction of about 50 G cm-1
and allowing for water preak suppression (δ = 4.8 ppm in D2O). Experiments were
carried out using a 5 mm BBI probe and the temperature was 298K. The mixing time was
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300 ms water suppression experiments. Chemical shifts were reported in parts per million
(ppm) for 1H-NMR on the δ scale based on the middle peak (δ = 2.50 ppm) of the
dimethyl sulfoxide (DMSO)-d6 solvent as an internal standard, or 4.8ppm for deuterium
hydroxide (D2O) experiments. Dialysis and solvent exchange of CPNs were conducted
using an Ultrafiltration Stirred Cell (Millipore, Billerica, MA, USA) with membrane
filters [Ultracel ultrafiltration disc, molecular weight cutoﬀ (MWCO): 30 kDa]. Tables
and graphs were plotted using Origin 8 software (OriginLab, Northampton, MA, USA).
2.6.2. Monomer Synthesis
Monomer 1 (M1) was synthesized according to Scheme 1. tert-butyl 2,2'azanediylbis(ethane-2,1-diyl)dicarbamate 1 and 2-(2-(2-chloroethoxy)ethoxy)ethyl 4methylbenzenesulfonate 2 were synthesized according to literature procedures.20,21
Condensation of 2 and 2,5-diiodohydroquinone in the presence of K2CO3 in 2-butanone
resulted in 3. Reaction of 1 with 3 using K2CO3 base in acetonitrile resulted in the
formation of M1. 3 and M1 were fully characterized by NMR and mass spectroscopy.
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Sccheme 1: Synth
hetic route tow
wards monomer M1. Reagentts and conditioons: i) BocON,,TEA, THF, 0oC, 3h;
ii)) TsCl, TEA, MC,
M room tem
mp., overnight; iii) 2,5-diiodohhydroquinone, K2CO3, 2-butaanone, reflux, 1 day;
iv
v) K2CO3, MeC
CN, Reflux, 3 days.
d

1,,4-bis(2-(2-((2-chloroethoxy)ethoxy)eethoxy)-2,5- diiodobenzeene (3): A suspension of
co
ompound 2 (5.89
(
mmol;; 1.9 g), 2,5-diiodohydrooquinone (2.776 mmol; 1 g) and potasssium
caarbonate (8.28 mmol; 1.14 g) in 40 mL of 2-buutanone and was refluxeed for 1 dayy. The
mixture
m
was concentrated
c
d in vacuo an
nd diluted w
with 30 mL oof ethyl acettate. The sollution
was
w washed with
w brine (10 mL x3), dried (Na2S
SO4), and evvaporated in vauo. The ccrude
prroduct was purified by column chrromatographhy (silica geel, ethyl aceetate/ hexanee(1:5,
v//v) and Yield: 1.5 g (83%
%).1H-NMR
R(400 MHz) : δ = 7.22 (ss, 1H, Ar-H)), 4.09 (t, 2H
H, ArO-CH
O
6 , 3.87 (t, 2H, CH2O,, J = 6), 3.882-3.74 (m, 4H, OCH2C
CH2), 3.69 ((t,2H,
2, J = 6)
CH
C 2Cl), 3.61 (t, 2H, OC
CH2, J = 6).

13

C-NMR(4400 MHz) : δ = 153.133, 123.52, 886.46,

72.01, 71.43
3, 71.15, 70.80,
7
70.3
33, 69.70, 42.83. HR
RMS (FTIC
CR): Calcd. for
C18H26Cl2I2O6 [M+Na]+: = 679.9534;; found [M+N
+Na]+: 679.95529.
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tert-butyl

2,2',2'',2'''-[2,2'-(2,2'-[2,2'-(2,5-diiodo-1,4-phenylene)bis(oxy)bis(ethane-2,1-

diyl)]-bis-(oxy)bis(ethane-2,1-diyl)]bis(oxy)bis(ethane-2,1-diyl)]bis(azanetriyl)tetrakis(ethane-2,1-diyl)-tetracarbamate (M1): A suspension of compound 1 (1.51
mmol; 1 g), compound 3 (3.17 mmol; 0.96 g) and potassium carbonate (3.171 mmol;
0.28 g) in 40 mL of MeCN was refluxed for 3 days. The mixture was concentrated in
vacuo and diluted with dichloromethane 30 mL. The solution was washed with brine (10
mL x3), dried (Na2SO4), and evaporated in vacuo. The crude product was purified by
column chromatography (silica gel, ethyl acetate/hexane (1:1, v/v). Yield: 0.4g (44%)
Rf=0.47 (3:1 ethyl acetate/hexane). 1H-NMR(400 MHz) : δ = 7.25 (s, 1H, NH-COO),
7.23 (s, 1H, Ar-H), 4.10 (t, 2H, Ar-O-CH2, J = 6) , 3.90 (t, 2H, CH2O, J = 6), 3.82 (t, 2H,
OCH2, J = 6), 3.68 (t, 2H, OCH2, J = 6), 3.52(br,2H, OCH2), 3.14 (br, 4H, CH2 nHBoc, J
= 6), 2.68 (br,2H,CH2 nH), 2.62 (br,4H, NHCH2) 1.45 (s, 18H, OC(CH3)3); 13CNMR(400
MHz): δ = 156.9, 144.3, 121.1, 83.7, 77.2, 70.6, 70.4, 70.3, 70.1, 59.1, 54.2, 53.7, 51.2,
50.7, 38.9, 27.3. HRMS (FTICR): Calcd. for C46H82I2 n6O14 [M+H]+: 1197.4051; found
[M+H]+: 1197.4032.
Monomer 2 (M2) was synthesized according to Scheme 2. tert-butyl 2-(2-hydroxyethoxy)ethylcarbamate

4,

methylbenzene-sulfonate

2-(2-(tert-butoxycarbonylamino)ethoxy)ethyl
5,

and

tert-butyl

4-

2,2'-[2,2'-(2,5-diiodo-1,4-

phenylene)bis(oxy)bis(ethane-2,1-diyl)]bis-(oxy)bis(ethane-2,1-diyl)dicarbamate 6 were
synthesized

according

to

literature

procedures.22-24

Coupling

of

6

with

trimethylsilylacetylene using Sonogashira coupling yielded compound 7, which was
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trrimethylsilyll-deprotected
d to yield M2. Compounnds 7 and M2 were fullyy characterizeed by
NMR
N
and maass spectrosccopy.

Sccheme 2: Syntthetic route tow
wards monom
mer M2. Reageents and condittions: i) Boc2O
O, MC, room temp.,
ov
vernight; ii) TssCl, TEA, MC
C, room temp., overnight; iii)) 2,5-diiodohyddroquinone, K2CO3, DMF, 80oC, 1
daay; iv) Trimeth
hylsilylacetylen
ne, Pd(PPh3)2Cl
C 2, CuI, diisoppropylamine, T
THF, 60oC, 12 h; v) K2CO3, M
MeOH,
ro
oom temp., oveernight.

teert-butyl

2,2'-(2,2'-(2,
2
5-bis[(trimeethylsilyl)ethy
hynyl)-1,4-phhenylene)biss(oxy)bis-(ethhane-

2,,1-diyl)]bis-(oxy)bis(ethane-2,1-diyl)
l)dicarbama te (7): Com
mpound 6 (2.03 mmol, 11.5 g)
was
w added to
o a Schlenk flask
f
fitted with
w a stir baar, Pd(PPh3) 2Cl2 (0.2033 mmol, 1466 mg)
an
nd CuI (0.10
00 mmol, 20
0 mg). A solu
ution of THF
F (20 mL) annd diisoproppylamine (100 mL)
was
w then ad
dded to the reaction mixture.
m
Sub sequently, ttrimethylsilyylacetylene (5.10
mmol,
m
0.7 mL
L) was addeed to the reaaction mixtuure. The reacction was alllowed to prooceed
fo
or 12 h at 60
6 °C, cooled to room temperaturre and the ssolvent was evaporated.. The
su
uspension was
w re-dissolved with meethylenechlooride, washeed with satuurated ammoonium
ch
hloride (2 ×3
30 mL), and
d then dried over
o
magnessium sulfate. The solvennt was evapoorated
to
o produce dark brown oil,
o which was
w purified by columnn chromatogrraphy (silicaa gel,
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ethyl acetate/ hexane (4:1, v/v). Yield : 0.94g ( 71 %). 1H-NMR(400 MHz) : δ = 7.23 (s,
1H, Ar-H), 5.0 (s, 1H, CH2-NH), 4.10 (t, 2H, Ar-OCH2, J = 6), 3.81 (t, 2H, OCH2, J = 6),
3.83 (t, 2H, OCH2, J = 6), 3.65 (s, 1H, ArCCH), 3.36 (q, 2H, CH2 nH, J = 6), 1.43 (s, 10H,
OC(CH3)3), 0.05 (s, 9H, TMS).

13

C-NMR(400 MHz) : δ = 171.1, 156.0, 154.0, 118.1,

114.5, 100.8, 79.1, 77.5, 71.9, 70.6, 69.6, 68.0, 60.4, 53.5, 41.3, 28.4, 21.0, 19.2, 14.2.
HRMS (FTICR): Calcd. for C34H56 n2O8Si2 [M+H]+: 677.3648; found [M+H]+: 677.3644.

tert-butyl

2,2'-[2,2'-(2,5-diethynyl-1,4-phenylene)bis(oxy)bis(ethane-2,1-diyl)]bis(oxy)-

bis(-ethane-2,1-diyl)dicarbamate (M2): A 20 mL vial was charged with compound 8
(1.42 mmol, 0.400 g), Potassium carbonate (0.70 mmol, 0.100 g) 15 mL of MeOH and
left to stir overnight at room temperature. The resulting mixture was gravity filtered, the
solvent was evaporated and the reaction mixture was purified by column chromatography
(silica gel, ethyl acetate). Yield : 0.34g (90 %). 1H-NMR(400 MHz) : δ = 7.00 (s, 1H, ArH), 5.0 (s, 1H, CH2-NH), 4.15 (t, 2H, Ar-OCH2, J = 6), 3.81 (t, 2H, OCH2, J = 6), 3.65 (t,
2H, OCH2, J = 6), 3.39 (s, 1H, ArCCH), 3.36 (q, 2H, CH2 nH, J = 6), 1.56 (s, 10H,
OC(CH3)3); 13C-NMR(400 MHz) : δ = 156.7, 154.1, 118.3, 113.7, 83.0, 79.5, 71.9, 70.6,
69.3, 69.25, 40.7, 28.4. HRMS (FTICR): Calcd. for C28H40

n2O8

[M+H]+: 533.2857;

found [M+H]+: 533.2849.

Monomer 3 (M3) was synthesized according to Scheme 3. 2-(2-methoxyethoxy)ethyl 4methyl-benzenesulfonate 8, 1,4-diiodo-2,5-bis(2-(2-methoxyethoxy)ethoxy)benzene 9,
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(2
2,5-bis(2-(2--methoxyeth
hoxy)ethoxy))-1,4-phenyllene)bis(ethyyne-2,1diyl)bis(trimeethylsilane)

10
0,

methoxyethox
m
xy)ethoxy)benzene

M3
M

were

aand

1,4-diethyynyl-2,5-bis((2-(2-

synthesized

accordingg

to

literrature

prrocedures.25

Sccheme 3: Synth
hetic route tow
wards monomerr M2. Reagentts and conditionns: i) TsCl, TE
EA, MC, room temp.,
ov
vernight; ii) 2,5-diiodohydrroquinone, K2CO3, DMF, 80oC, overniight; iii) Trim
methylsilylacettylene,
Pd
d(PPh3)2Cl2, CuI,
C
diisopropy
ylamine, THF, 60oC, 12 h; iv) 1 m KOH
H(aq), THF, M
MeOH, room temp.,
ov
vernight.

2.6.3. Polymeer Synthesiss and Chara
acterization
n
ure
2.5.3.1. Geneeral Procedu
A Schlenk flask
fl
was charged
c
with
h aryl halidde monomer (1.0 eqiv)) and diactyylene
monomer
m
(1.0 equiv), alo
ong with Pd
d[(PPh3)2Cl2 ] (0.2 equivv) and CuI ((0.95 equiv). The
Schlenk flask
k was evacu
uated and filled with N2 three timees. A solutiion of anhyddrous
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dimethylformamide (DMF) (4 mL) and freshly distilled trimethylamine (1 mL) was
degassed, and 1 mL of the mixed solution was transferred to the Schlenk flask using a
cannular needle. The reaction was heated at 70 °C for14 h. The solution was then cooled
to room temperature and transferred dropwise to cold ethyl ether, resulting in
precipitation. After centrifugation (2 min, 4000 rpm), the supernatant was decanted, and
the precipitate was redissolved in DMF (1 mL) for further purification. See Scheme 4.
2.6.3.2. CPN Formation. Boc-deprotection of the polymer was carried out by mixing a
solution of polymer in DMSO-d6 with acetic acid (2 mL) and trifluoroacetic acid (1 mL)
and allowed to stir at room temperature for 5 days. The mixture was then added to acetic
acid (20 mL), allowed to stir overnight, and centrifuged, and supernatant was added
dropwise (2 drops/s) to 500 mL water (18 Ω) while stirring. Using a solvent-resistant stir
cell fitted with a 30 kDa-MWCO membrane, the solution was concentrated to
approximately 10 mL, and dialyzed against 1 L of water. The resulting solution was
further dialyzed in a 10 KDa membrane for 3 days. The solution was subsequently
filtered through a Teflon (PTFE) syringe filter (0.45 μm) and used for further analysis.
Deprotection was confirmed with 1H-NMR. See Scheme 4.
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Sccheme 3: Syntthetic route tow
wards CPN-1, CPN-2 and C
CPN-3. Reagennts and conditioons: i) Pd(PPhh3)2Cl2,
CuI, TEA, DMF
F , 70oC, 14 h; ii) TFA, AcOH
H, DMF, room
m temp., 5 days..

P1.
P Using th
he general prrocedure desscribed abovve, the polym
merization of monomer 9 (32
mg,
m 0.044 mmol)
m
and monomer 13 (20 m
mg, 0.044 m
mmol) in tthe presencce of
Pd[(PPh3)2Cl2] (3 mg, 0.0044
0
mmo
ol) and CuII (0.2 mg, 0.0022 mm
mol) yielded PPE
polymer P-1 ( 32 mg, 71%). Molecu
ular weight of boc-prottected polym
mer was obtained
nd characterrized. Resullting mixture was puriffied by preccipitation in cold ethyl ether
an
(x
x3). An aliqu
uot was rediissolved in THF
T
and moolecular weigght obtained and photophhycal
prroperties ch
haracterized.. The rest of the matterial was ddissolved inn DMSO-d6 and
ch
haracterized
d using 1H-N
NMR. CPN
N formation was then carried out as describeed in
general proceedure to yield
d CPN-1.
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P1:
P GPC: Mw =24.43 kD
Da; Mn= 16.4
4 kDa; PDI = 1.49. UV λmax = 427 nnm; fluo λmaxx(400
nm
m ex) =471 nm; QY = 41%
4
in DMF
F. 1H-NMR(4400 MHz) : δ = 7.35 (brr, 1H, Ar-H),, 6.87
(b
br, 0.5H, NH
HCOO), 4.08
8 (br, 2H, Ar-OCH
A
CH2O), 3.822 (br, 2H, OC
CH2),
2), 3. 91 (br, 2H C
3.58 (br, 2H, CH2O), 3.4
48 (br, 2H, OCH
O 2), 3.344 (br, 2H, C
CH2O), 3.27 (br, 2H, OC
CH2),
2.72 (br, 3H,, OCH3), 1.4
47 (s, 8H, OC(CH
O
at): ν = 33722 (br), 29822 (w),
3)3). FT-IR (Nea
2935 (m), 287
75 (s), 1710 (vs; C=O), 1513 (vs), 11461 (w), 14425 (m), 14225 (m), 13933 (m),
1363 (s), 1276 (s), 1219 (s),
( 1172 (m)), 1120 (m), 1060 (m), 11033 (m).
CPN-1:
C
UV λmax = 433 nm; fluo λmax
nm; QY = 33% in waterr. 1Hm (400 nm ex) =496 n
NMR(600
N
MHz)
M
: δ = 7..36 (br, 1H, Ar-H), 4.3--3.0 (br, 23H
H, -OCH2-CH
H2- chains),, 1.30
(ss, 0.21H). FT-IR (Neat): ν = 3374 (br),
(
2982 (w
w), 2935 (m
m), 2875 (s),, 1674 (br), 1610
(w
w), 1500 (m
m), 1461 (w),, 1423 (w), 1390 (w), 1360 (m), 12279 (w), 12550 (w), 12133 (br),
1104 (br), 1059 (br), 1035
5 (m).

Figure 2.6. 1H-N
NMR for polym
mer CPN-1 in D2O
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Figure 2.7. FT-IR for polymerr P1 (Neat)

Figure 2.8. DLS
S for polymer CPN-1
C
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Figure 2.9. ZP for polymer CPN-1

P2. Using the general procedure described above, the polymerization of 6 (30 mg, 0.056
mmol) and monomer M2 (41 mg, 0.056 mmol) in the presence of Pd[(PPh3)2Cl2] (4 mg,
0.0056 mmol) and CuI (0.3 mg, 0.0028 mmol) yielded PPE polymer P2 ( 44 mg, 73%).
Resulting mixture was purified by precipitation in cold ethyl ether (x3). An aliquot was
redissolved in THF and molecular weight obtained and photophycal properties
characterized. The rest of the material was dissolved in DMSO-d6 and characterized
using 1H-NMR. CPN formation was then carried out as described in general procedure to
yield CPN-2
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P2:
P GPC: Mw =16.9 kDaa; Mn= 11.8 kDa; PDI = 1.43. UV λmax = 432 nnm; fluo λmaxx(400
nm
m ex) =475 nm; QY = 37% in DM
MF. 1H-NMR
R (400 MHzz, DMSO-d6, δ): 7.16 (ss, 1H,
Ar-H),
A
6.72 (s,
( 0.2H, NH
H-Boc), 4.21 (br, 2H, Arr-OCH2), 3.80 (br, 2H, CH2O), 3.666 (br,
2H
H, OCH2), 3.52
3
(br, 2H
H, CH2 nH), 1.37 (s, 8H, C(CH3)3). F
FT-IR (Neatt): ν = 33666 (br),
2933 (w), 2865 (s), 1704
4 (vs; C=O), 1507 (vs), 1457 (w), 1423 (w), 1365 (s), 12777 (w),
1247 (w), 121
19 (s), 1172 (w), 1108 (ss), 1057 (s), 1026 (w), 945 (s), 860 ccm−1 (m).
CPN-2:
C
UV λmax = 427 nm;
n fluo λmaxx(400 nm ex)) =492 nm; QY = 2% inn water. 1H-N
NMR
(6
600 MHz, D2O, δ): 7.03
3 (br, 1H, Ar-H),
A
4.24- 2.76 (br, 100.74H, OCH
H2CH2OCH2C
CH2),
1.36 (s, 0.46H
H). FT-IR (N
Neat): ν = 3417
3
(br), 22925 (w), 28865 (s), 16477 (br), 14955 (w),
14
462 (w), 1418 (w), 1357
7 (w), 1283 (w), 1205 ((s), 1094 (s),, 1040 (w), 936 (w), 841 (w)
cm
m−1.

Figure 2.10. 1H-NMR for poly
ymer CPN-2 in
n D 2O
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Figure 2.11. FT
T-IR for polymer P2 (Neat)

Figure 2.12. DL
LS for polymerr CPN-2
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Figure 2.13. ZP for polymer CPN-2

P3. Using the general procedure described above, the polymerization of monomer 4 (65
mg, 0.054 mmol) and monomer 13 (32 mg, 0.054 mmol) in the presence of
Pd[(PPh3)2Cl2] (8 mg, 0.0054 mmol) and CuI (0.4 mg, 0.0022 mmol) yielded PPE
polymer P3 ( 45 mg, 61%). Resulting mixture was purified by precipitation in cold ether
(x3). An aliquot was redissolved in THF and molecular weight obtained and photophycal
properties characterized. The rest of the material was dissolved in DMSO-d6 and
characterized using 1H-NMR. CPN formation was then carried out as described in
general procedure to yield CPN-3.
P3: GPC: Mw =17.5 kDa; Mn= 10.7 kDa; PDI = 1.64. UV λmax = 420 nm; fluo λmax(400
nm ex) =469 nm; QY = 35% in DMF. 1H-NMR(400 MHz) : δ = 7.70-6.95 (br, 1H, ArH), 4.0-3.24 (br, 42H, OCH2CH2), 2.30-1.94 (br, 6H, NCH2CH2 nH), 1.30 (s, 10H,
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OC(CH
O
F
(Neat)): ν = 3357 (br),
(
2909 (bbr), 1656 (vss; C=O), 15000 (w), 14411 (w),
3)3). FT-IR
14
421 (w), 139
91 (w), 1367
7 (m), 1340 (w), 1316 ((w), 1280 (w
w), 1250 (m)), 1228 (w), 1208
(w
w), 1162 (m)), 1103 (m), 1060 (br), 1034
1
(br).
CPN-3:
C
UV λmax = 420 nm; fluo λmax
nm; QY = 22% in waterr. 1Hm (400 nm ex) =496 n
NMR(600
N
MHz)
M
: δ = 7.70-6.45 (brr, 1H, Ar-H)), 4.3-2.5 (bbr, 28H, OCH
H2-CH2- chaains),
2.17 (br, 4H, NCH2CH2 nH) FT-IR (N
Neat): ν = 3369 (br), 29982 (w), 29336 (m), 28755 (br),
1685 (br), 1631 (br), 150
00 (br), 1460
0 (w), 1426 ((s), 1361 (brr), 1358 (br)), 1279 (m), 1249
w), 1203 (vss), 1181 (w), 1103 (br), 1047
1
(br).
(w

Figure 2.14. 1H-NMR for poly
ymer CPN-3 in
n D 2O
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Figure 2.15. FT
T-IR for polymer P3 (Neat)

Figure 2.16. DL
LS for polymerr CPN-3
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Figure 2.17. ZP for polymer CPN-3

Polymer P4. Polymer synthesis, deprotection, CPN fabrication, and characterization is
described elsewhere.26
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Figure 2.18. DLS for polymer CPN-4

Figure 2.19. ZP for polymer CPN-4
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2.6.3.3. Polymer Deprotection
Confirmed using 1H-NMR data by looking at characteristic Boc proton peak (1.36ppm)
and ~1700 cm-1 infrared band for the carbonate (C=O) group. IR samples were prepared
by lyophilization to prepare neat sample. IR scans from 4000 to 700 cm-1 are presented
below, depicting absence of boc-carbonate group and confirming deprotection.
2.6.3.4. Gel Permeation Chromatography
Samples dissolved in THF were filtered through a Teflon (PTFE) syringe filter (0.25 μm)
three times. The average molecular weight (Mn) and polydispersity index (PDI = Mw/Mn)
of the polymers were determined by gel permeation chromatography (GPC) against
polystyrene standards using a Shimadzu high performance liquid chromatography
(HPLC) system fitted with PLgel 5 μm MIXED-D columns and SPD-20A ultraviolet−
visible (UV−Vis) detector.
2.6.3.5. Dyniamic Light Scattering (DLS)
Hydrodynamic radii and Zera potentials (ZP) were determined by dynamic light
scattering technique using a Zetasizer nano−ZS (Zen 3600, Malvern Instruments Ltd.).
Three polymer aliquots of 500µM CPN were independently prepared by filtering through
a Teflon (PTFE) syringe filter (0.45 μm). DLS samples loaded in a low volume (1.5 mL)
disposable cuvette, and Zeta potential samples into disposable capillary cell. Averages
and standard deviations reported in the main text. Figures S7-14, show representative
reports for polymer CPN-1, -2, -3 and -4.
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2.6.4. Cell Culture
2.6.4.1. General
HeLa cells (human cervical cancer, purchased from ATCC), seeded into a 100 x 20 mm
style sterile tissue culture dish (#353003 BD Falcon, Durham, NC, USA), cultured in
minimum essential medium (MEM)/Earle’s balanced salt solution (EBSS) (400 μL,
HyClone, SH30024) medium containing 10% fetal bovine serum (FBS) and 100 U/m
penicillin for 24 h under 5% CO2 at 37 °C, and subcultured every 48 hours. pHRhodo
Dextran 10kDa (#P10361 Molecular probes, Life technologies, New York, USA) and
BODIPY-TR

C5

-ceramide-BSA

complex

(#B34400

Molecular

probes,

Life

technologies, New York, USA) were used for endosome and Golgi apparatus staining,
respectively.
2.6.4.2. Microscopic Imaging
10,000 HeLa cells were seeded into a glass-bottomed eight-well chamber slide (Lab-Tek
Thermo Scientific) and cultured in a minimum essential medium (MEM)/Earle’s
balanced salt solution (EBSS) (400 μL) medium containing 10% fetal bovine serum
(FBS) and 100 U/m penicillin for 24 h under 5% CO2 at 37 °C. 80 μL of 20 μM CPNs in
water was added to the culture medium directly, and the cells were further cultured
overnight (final CPN concentration: 4 μM). For endosome staining, pHRhodo Dextran
10kDa (5µM) was incubated for 30 min at 37oC. For Golgi apparatus staining, BODIPYTR C5 -ceramide-BSA complex (final 10 μM) was incubated for 30 min at 4 °C. After
washing with fresh medium, the cells were further incubated for 30 min at 37 °C. A 1 μL
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aliquot of Hoechst (5 μg/mL) was added to the culture medium and incubated with the
cells for 10 min at 37 °C, and washed two times with phosphate buﬀered saline (PBS).
The cells were fixed with 4% paraformaldehyde for 10 min. Fluorescent images of the
cells were obtained using a DeltaVision Elite Microscope System (Applied Precision,
Issaquah, Washington, USA) equipped with bandpass filters such as blue (410−460 nm,
Hoechst), green (500−550 nm, CPNs), and red (595-635 nm, Golgi and endosome). Top
and bottom of the chosen cells was identified, and a Z-stack plot was imaged for each
channel.
2.6.4.3. Colocalization study
Z-stack microscope images of each sample was obtained as described above.
Colocalization analysis was conducted for three independent cells per polymer and per
organelle (Golgi apparatus and endosome). Colocalization analysis was conducted using
the microscope software (Softworx 5.0 application, Applied Precision, Issaquah,
Washington, USA). Region of interest (ROI) was selected to contain all of the cell.
Pearsons Correlation Coefficient (PCC) was used to determine colocalization. Negative
control of colocalization was performed by analysis of blue and green channels staining
the nucleus and CPN, respectively. Three independent images of an entire cell were
selected and analysed to increase the analysis objectivity. A representative example is
shown in figure 2.20.
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Figure 2.20. Example
E
of miicroscopic images and PCC aanalysis. HeLa cells incubated with CPN-3 and
PCC co-localizaation analysis of
o the region off interest. Conttrol and experiimental
co-localizattion using bluee/green and greeen/red channeels, respectivelyy.

Experimental
E
l colocalizatiion PCC vallues were obbtained using the green and red chaannels
sttaining the CPN
C
and the target org
ganelle (Golggi or endosoome). Repreesentative im
mages
sh
hown in figu
ures S-16 an
nd S-17. Quaantification and statiticaal analysis w
was performeed by
av
veraging PC
CC values between the in
ndependent ccells per polyymer and peer organelle. Oneway
w ANOVA
A followed by Tukey means
m
separration methhod was connducted for PCC
co
olocalization
n values betw
ween samplees of same o rganelle usinng Origin 8 software.

2.6.4.4. Toxiccity Assay HeLa
H
cells (∼10
(
000 ceells/well) in 200 μL of ccomplete meedium
were
w
seeded into a 96-well plate and
d cultured foor one day iin a 5% CO22 incubator at 37
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°C. CPNs with various concentrations (5 to 40 μM) were added and incubated overnight.
To measure toxicity, 10 μL of WST-1 [2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4disulfophenyl)-2H-tetrazolium] (Cayman Chemical, Ann Arbor, MI, USA) solution was
added into each well, and the plate was further incubated for 4 h at 37 °C. Cell viability
was compared by measuring absorbance values at 450 nm using a microplate well reader
(Synergy 2, BioTek, Winooski, VT, USA). Relative cell viability as a function of CPN
concentration was obtained by subtracting absorbance values of each sample well with
control CPN absorbance at 450 nm.
2.7.
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CHAPTER III

COMPLEXATION-DEPENDENT SUBCELLULAR LOCALIZATION
AND UPTAKE
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3.1.

Abstract

The cellular uptake and subcellular localizations of conjugated polymer nanoparticles
(CPNs) is significantly affected upon complexation with polysaccharides. Incorporation
of short ethylene oxide onto amine-containing CPNs afford polyplexes with reduced late
endosome/lysosome localization and enhanced cellular uptake. CPNs with only amine
side-chains, regardless of backbone structure, did not exhibit enhanced cellular uptake.
3.2.

Introduction

Semiconducting conjugated polymer nanoparticles (CPNs) have attracted much attention
for cellular labelling,1 sensing,2 and delivery of therapeutics. 4 Upon treating non-aqueous
soluble conjugated polymers (CPs) under various particle formation conditions, they can
form non-toxic soft nanoparticles for cellular labelling and nucleic acid delivery.5
Previously, we fabricated various cationic CPNs by treating a non-aqueous soluble,
primary amine-containing poly(p-phenyleneethynylene) (PPE) and flexible-linker
containing poly(p-phenylenebutadiynylene) (PE-d-PPB) with organic acids followed by
dialysis.6 The CPN’s subcellular localizations and toxicity were dependent on the
chemical structure of the side chain and backbone structures. Amine-containing PPEs and
PE-d-PPBs exhibited high Golgi localization with no toxicity. Upon incorporation of
short ethylene oxide chains Golgi localization significantly decreased. Recently, we
demonstrated that upon complexation with hyaluronic acid (HA), CPNs form fluorescent
core-shell nanoparticles exhibiting photophysical, size, and morphological changes.7
These changes were enhanced when the CPN contained a semi-flexible linker. The
resulting polymer-polysaccharide complex (polyplex) exhibited improved cancer cell
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specificity towards human cervical carcinoma (HeLa) cells. Several nanocarrier platforms
have reported similar formulations with naturally-derived polymers.8 Upon preparation,
these formulations these formulations have afforded nanocarriers with increased stability,
improved pharmacokinetics, improved cancer-specificity and lower toxicity.
While active targeting by CPNs remains highly desirable, it becomes clear that to
improve the drug efficacy the nanocarrier should not only facilitate successful delivery
into specific cell types or tissues, but direct the drug to its appropriate intracellular
destination. Because most drugs require delivery specific organelles, the increased
cancer-cell specificity and decreased carrier toxicity will not improve delivery efficiency
if the drugs are not delivered to the proper organelle. Therefore, understanding how
subcellular localization and uptake are affected upon polysaccharide complexation is
paramount to improving overall labelling and delivery efficiency.
Work towards understanding how CMC or HA complexation affects nanoparticle uptake
efficiency and subcellular fate has been limited. Hyaluronic acid has been reported to
display

molecular-weight

dependent

endocytosis

pathways.9

Receptor-mediated

endocytosis and macropinocytosis of bulk phase HA have been reported for low (104
kDa) and high molecular (106 kDa) weight HA, respectively. Although mechanistic
studies of CMC uptake mechanisms remain limited, various compounds incorporating
CMC or using CMC hydrogels report late endosome, and lysosomal co-localization and
improved HeLa cell uptake.10 Previously, we reported that core-CP shell-HA
nanoparticles can be obtained when semi-flexible CPs were treated with polyanionic HA,
while non-flexible CPs produce random complexes upon HA treatment. 11 Therefore, we

65

hy
ypothesize that
t
upon co
omplexation of CMC or HA with seemi-flexible linker-contaaining
CPNs,
C
the ressulting polyp
plex will ex
xhibit signifiicant polysacccharide-likee cellular upptake,
su
uch as enhan
nced cellularr uptake and
d significant late endosoome/lysosom
me localizatioon, in
ad
ddition to th
he already reported
r
can
ncer cell-speecificity. Wee did not exxpect the ceellular
up
ptake enhancement orr increased late endoosome/lysosoome localizzation to bbe as
siignificant in non-flexiblee CPs due to
o the random
m nature of thhe complex.
To
T test the hy
ypothesis, we
w fabricated
d three CPNss from polym
mers exhibitting differentt side
ch
hain (CPN-1
1 and CPN--2) and back
kbone structu
tures (CPN-33) (Figure 1). Synthesis and
ch
haracterizatiion of CPN
N-1 and CP
PN-2 were rreported in Chapter 2. Because oof the
particle form
mation mechanism (i.ee., moleculaar weight independentt phase innverse
prrecipitation driven by aq
queous insollubility of CP
Ps),12 the shhapes and hyydrodynamicc radii
of CPNs are relatively
r
constant.13 CP
PN-2 was utiilized to test the ethylenee oxide (EO))-

Figure 3.1. Ch
hemical structu
ures of aminee-containing C
CPs. Poly(p-phhenyleneethynyylenes) (PPEs)) with
diifferent side chains
c
(CPN-1
1, CPN-2) and poly(p-phennylenebutadiynnylene) (PPB) containing a small
am
mount of flexib
ble unit in the backbone
b
(CPN
N-3) were syntthesized and ceellular behavioor was compareed.
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side chain effects from non-EO containing CPN-1 and the resulting complexation and
cell uptake behavior. CPN-3 was designed to test the effect the biodegradable-linker has
on the complexation and uptake behavior compared to CPN-2.
Subcellular localization of CPNs was monitored by fluorescent microscopic imaging.
Overnight treatment of HeLa cells with CPNs (green) were co-stained with pHRhodo
Dextran (10kDa) (red) for labelling acidic organelles (i.e., endosomes and lysosomes)
after overnight CPN/polyplex treatment. The Pearson's Correlation Coefficient (PCC)
was used to examine co-localization evaluation, with scores of 0 and 1 correspond to uncorrelated and perfectly linearly correlated colors, respectively. Mean PCC scores from
three independent images of an entire cell were selected and analyzed to examine
analysis variance. Changes in cellular uptake were measured using flow cytometry for
polymers by themselves and after complexation with CMC or HA.
3.3 Results and Discussion
Subcellular Localization
To test how the CPN’s subcellular localization is influenced upon CMC or HA
complexation, the CPN polyplexes were incubated with human cervical carcinoma cells
(HeLa) overnight. As shown in Figure 3.2, CPN-2 exhibited no significant change to late
endosome/lysosome localization upon complexation with HA or CMC. CPN-1
polyplexes exhibited significant decreases in late endosome/lysosome localization,
suggesting a decrease in adsorptive endocytosis. If CPN-1’s high endosomal/lysosomal
co-localization is the result of the polymer’s non-specific interaction with generic
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co
omplementaary binding sites,
s
like neegatively chharged heparrin sulfate proteoglycans and
hy
ydrophobic membrane lipids in th
he cell mem
mbrane, thenn polyplex fformation shhould
reeduce this non-specificc interaction
n; this deccrease, shouuld in turn,, affect thee late
en
ndosome/lyssosome colo
ocalization. However, thhis should aalso result iin an increaase to
laate/endosom
me/lysosome colocalizattion, as CM
MC/HA com
mplexation should impprove
macropinocyt
m
totic uptake. Materials that
t
are inteernalized viaa macropinossomes have been
reeported to often
o
diffusio
on out of th
he vesicle annd into the ccytosol.14,15 Macropinossomal
esscape could
d be occurrring for both CPN-1 and CPN-22 polyplexees, howeverr, the
in
ncreased am
mine-density
y afforded by CPN-22 might m
make diffusiion out off the
macropinocyt
m
totic vesicle difficult.
Finally, CPN
N-3 polyplex
xes exhibiteed significannt increases to late enddosome/lysoosome
ocalization.
lo

It was exp
pected that CPN-3
C
wouldd exhibit thee most signifficant changee to

Figure 3.2. Qu
uantitative anallysis of co-loccalization using
ng the PCC alggorithm. Co-loocalization witth late
en
ndosome/lysosome significan
ntly decreased and increasedd for CPN-1 annd CPN-3, resspectively. Thee error
baar represents ±standard
±
deviiation (n=3). * p<0.005 wheen CPN is com
mpared to pollyplex (CPN+H
HA or
CPN+CMC).
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late endosome/lysosome colocalization because of core-CP shell-CMC/HA morphology
that is facilitated by the semi-flexible nature of the material. Indeed, this was indeed
observed for both CMC and HA polyplexes.
CPN Polyplex cellular uptake
To measure the CPN-polysaccharide polyplex accumulation was measured using flow
cytometry. Briefly, cellular uptake was measured after 2 hours and overnight (18 hours)
treatment. To measure the polyplex retention/clearance, cellular uptake was measured by
treating cells with the CPN for 2 hours, exchanging media, and allowing HeLa cells to
incubate overnight (16 hours). Any remaining CPN signal within the cell can be
measured to compare relative retention between CPNs. Cellular uptake comparison
between these polyplexes was made possible by normalizing the mean fluorescence
measurements obtained from the flow cytometer.
The cellular uptake by the non-flexible CPNs, and the resulting polyplex upon HA and
CMC complexation are summarized in figure 3.3. The resulting polyplex of CMC/HA
with CPN-1 resulted in a 2-fold enhancement into HeLa cells for all treatment times
tested. There was no significant difference between the uptake facilitated upon CMC or
HA complexation. The significant increase in uptake is interesting, when coupled with
the fact that late endosome/lysosome localization significantly decreased for the CPN-1
polyplexes. The combined results provide further evidence supporting the subcellular
localization changes exhibited by CPN-1 resulting from decreased non-specific
interaction with generic complementary binding sites, like negatively charged heparin
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a)

b)

Figure 3.3. Celllular uptake of
o (a) CPN-1 and (b) CPN-22 upon HA annd CMC compplexation. Measured
ussing flow cytometry where fluorescence
f
signal was norm
malized using tthe CPN’s quaantum yield ressulting
reelative uptake. The error bar represents ±sttandard deviatiion (n=3). * pp<0.005 when CPN is compaared to
po
olyplex (CPN+
+HA or CPN+C
CMC).
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su
ulfate proteo
oglycans and
d hydrophobiic membranee lipids in thhe cell membbrane, resultting
frrom CMC an
nd HA comp
plexation.
The
T resulting
g polyplex beetween CMC
C and HA coomplexationn with CPN--2 did not exxhibit
an
ny of the uptake
u
enhaancement seeen with C
CPN-1.

In fact, the rresulting CPN-2

polyplexes ex
xhibited sign
nificant decrreases in HeeLa cell uptaake using alll three treattment
co
onditions. There was no
o significant difference inn uptake bettween CPN--2-HA and C
CPN2-CMC polyp
plex.
ible linker ccontaining CPN-3, andd the
Finally, the cellular upttake by thee semi-flexib
C
compllexation aree summarizeed in figuree 3.4.
reesulting polyplex upon HA and CMC
Similar to thee effect exhiibited by CP
PN-2, upon C
CMC and H
HA complexaation, CPN--3 did
not exhibit an
ny of the up
ptake enhanccement seen with CPN-1. The polyyplexes exhiibited
sm
mall but sign
nificant decrreases in HeL
La cell uptakke using all tthree treatment conditionns.

Figure 3.4. Celllular uptake of
o semi-flexiblle CPN-3 uponn HA and CM
MC complexatiion. Measuredd using
flow cytometry where fluoresccence signal waas normalized using the CPN
N’s quantum yiield resulting reelative
up
ptake. The erro
or bar represen
nts ±standard deviation
d
(n=3)). * p<0.005 w
when CPN is coompared to poolyplex
(C
CPN+HA or CP
PN+CMC).
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3.4. Conclusion
The significant decrease in uptake upon complexation with HA and CMC, coupled with
the subcellular changes that resulted in increased late endosome/lysosome localization
after overnight treatment, do not support our initial hypothesizes that CPN-3 would
exhibit the most significant cellular uptake enhancement. We expected improved uptake
due to the formation of core-CP shell-CMC/HA morphology that is facilitated by the
semi-flexible nature of the material. If the uptake is significantly influenced by the
complexing polysaccharide, then we expect the polyplex to exhibit improved
internalization via macropinocytosis. This phenomenon could be occurring for both
CPN-2 and CPN-3 polyplexes, however, the increased amine-density in both CPNs
might make diffusion out of the macropinocytotic vesicle difficult. There is further
evidence supporting this hypothesis, as CPN-1, containing half the amine density of
CPN-2 and CPN-3, indeed exhibits the uptake enhancement and decreased endosome
localization we expected from CPN-3. In conclusion the cellular uptake and subcellular
localizations

of

CPNs

were

significantly

affected

upon

complexation

with

polysaccharides. Incorporation of short ethylene oxide onto amine-containing CPNs
afford polyplexes with reduced late endosome/lysosome localization and enhanced
cellular uptake. CPNs with only amine side-chains, regardless of backbone structure, did
not exhibit enhanced cellular uptake. A detailed study in the endocytosis mechanisms for
the uptake of these polyplexes could shed light into this interesting phenomenon.

72

3.5.

Outlook

Since the writing of this chapter, a preliminary study of the endocytosis pathway of each
CPN-polysaccharide polyplex was performed. The endocytosis pathways for CPN-1,
CPN-2 were previously determined to be CvME/CME and CME/CvME, respectively
(see Chapter 2). CPN-3 was determined to be MPC. Upon complexation with HA, all
resulting HA-polyplexes exhibited MPC and CvME as their main and secondary
endocytosis pathways, respectively. This observed change in endocytosis pathway
occurred regardless of the nature of the polymer used. These results further support our
hypothesis. We had observed improved uptake due to the formation of core-CP shellCMC/HA morphology that is facilitated by the semi-flexible nature of the material. If the
uptake is significantly influenced by the complexing polysaccharide, then we expected
the polyplex to exhibit improved internalization via macropinocytosis. We did in fact
observe this phenomenon upon HA complexation. The effects on endocytosis pathway
were upon CMC complexation were not as significant, however. The resulting increase in
hydrodynamic radius of the CMC-polyplex could cause the observed changes, and
remains an interesting avenue for future work.
Further studies on polymers using semi-flexible CPNs here have revealed that the nature
of the conjugated backbone, and the amount of flexible linker play a crucial role in the
controlled aggregation of the resulting polyplex. In conclusion, the understanding the role
that backbone and the semi-flexible linker play in the controlled aggregation, and the
resulting biophysical properties, will continue to facilitate development of novel
multifunctional materials for labelling, sensing, and delivery.
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3.6.

Experimental Section

3.6.1. General
Chemicals, including solvents, were purchased from Fisher Scientific and used as
received. Deuterated solvents were purchased from Cambridge Isotope Laboratories
(Cambridge, MA). UV−vis spectra were recorded using a Varian Cary 50 Bio
spectrophotometer.

Fluorescence

spectra

were

obtained

using

a

FluoroLog-3

Spectrofluorometer (Jobin Yvon/ Horiba). 9,10-diphenylanthracene (QY = 1.0) in
cyclohexane was used as a fluorescence standard for QY determination. The average
molecular weight (Mn) and polydispersity index (PDI = Mw/Mn) of the polymers were
determined by gel permeation chromatography (GPC) against polystyrene standards
using a Shimadzu high performance liquid chromatography (HPLC) system fitted with
PLgel 5 μm MIXED-D columns and SPD-20A ultraviolet− visible (UV−vis) detector.
Nuclear magnetic resonance (NMR) spectra were recorded on a 400 MHz and 600 MHz
Avance Bruker NMR spectrometer. The 600 MHz NMR spectrometer is equipped with a
gradient system capable of producing magnetic field pulse gradients in the z-direction of
about 50 G cm-1 and allowing for water peak suppression (δ = 4.8 ppm in D2O).
Experiments were carried out using a 5 mm BBI probe and the temperature was 298K.
The mixing time was 300 ms water suppression experiments. Chemical shifts were
reported in parts per million (ppm) for 1H-NMR on the δ scale based on the middle peak
(δ = 2.50 ppm) of the dimethyl sulfoxide (DMSO)-d6 solvent as an internal standard, or
4.8ppm for deuterium hydroxide (D2O) experiments. Dialysis and solvent exchange of
CPNs were conducted using an Ultrafiltration Stirred Cell (Millipore, Billerica, MA,
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USA) with membrane filters [Ultracel ultrafiltration disc, molecular weight cutoﬀ
(MWCO): 30 kDa]. Tables and graphs were plotted using Origin 8 software (OriginLab,
Northampton, MA, USA).

3.6.2 Polymer Synthesis and Characterization
P3. A Schlenk flask was charged with of monomer 9 (32 mg, 0.044 mmol) and monomer
13 (20 mg, 0.044 mmol) in the presence of Pd[(PPh3)2Cl2] (3 mg, 0.0044 mmol) and CuI
(0.2 mg, 0.0022 mmol). The Schlenk flask was evacuated and filled with N2 three times.
A solution of anhydrous dimethylformamide (DMF) (4 mL) and freshly distilled
trimethylamine (1 mL) was degassed, and 1 mL of the mixed solution was transferred to
the Schlenk flask using a cannula needle. The reaction was heated at 70 °C for14 h. The
solution was then cooled to room temperature and transferred drop wise to cold ethyl
ether, resulting in precipitation. After centrifugation (2 min, 4000 rpm), the supernatant
was decanted, and the precipitate was dissolved in DMF (1 mL) to yield P3.
Molecular weight of boc-protected polymer was obtained and characterized. Resulting
mixture was purified by precipitation in cold ethyl ether (x3). An aliquot was dissolved in
THF and molecular weight obtained and photophysical properties characterized. The rest
of the material was dissolved in DMSO-d6 and characterized using 1H-NMR. CPN
formation was then carried out as described in general procedure to yield CPN-3.
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P3: GPC: Mw =24.43 kDa; Mn= 16.4 kDa; PDI = 1.49. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.35 (br, 1H, Ar-H), 6.87
(br, 0.5H, NHCOO), 4.08 (br, 2H, Ar-OCH2), 3.91 (br, 2H CH2O), 3.82 (br, 2H, OCH2),
3.58 (br, 2H, CH2O), 3.48 (br, 2H, OCH2), 3.34 (br, 2H, CH2O), 3.27 (br, 2H, OCH2),
2.72 (br, 3H, OCH3), 1.47 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w),
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m),
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m).
CPN-3: UV λmax = 433 nm; fluo λmax(400 nm ex) =496 nm; QY = 3% in water. 1HNMR(600 MHz) : δ = 7.36 (br, 1H, Ar-H), 4.3-3.0 (br, 23H, -OCH2-CH2- chains), 1.30
(s, 0.21H). FT-IR (Neat): ν = 3374 (br), 2982 (w), 2935 (m), 2875 (s), 1674 (br), 1610
(w), 1500 (m), 1461 (w), 1423 (w), 1390 (w), 1360 (m), 1279 (w), 1250 (w), 1213 (br),
1104 (br), 1059 (br), 1035 (m).

3.6.2.1 CPN Formation
Boc-deprotection of the polymer was carried out by mixing a solution of polymer in
DMSO-d6 with acetic acid (2 mL) and trifluoroacetic acid (1 mL) and allowed to stir at
room temperature for 5 days. The mixture was then added to acetic acid (20 mL), allowed
to stir overnight, and centrifuged, and supernatant was added drop wise (2 drops/s) to 500
mL water (18 Ω) while stirring. Using a solvent-resistant stir cell fitted with a 30 kDaMWCO membrane, the solution was concentrated to approximately 10 mL, and dialyzed
against 1 L of water. The resulting solution was further dialyzed in a 10 KDa membrane
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for 3 days. The solution was subsequently filtered through a Teflon (PTFE) syringe filter
(0.45 μm) and used for further analysis. Deprotection was confirmed with 1H-NMR.

3.6.2.2.Polymer Deprotection
Confirmed using 1H-NMR data by looking at characteristic Boc proton peak (1.36ppm)
and ~1700 cm-1 infrared band for the carbonate (C=O) group. IR samples were prepared
by lyophilization to prepare neat sample. IR scans from 4000 to 700 cm-1 are presented
below, depicting absence of boc-carbonate group and confirming deprotection.

3.6.2.3. Gel Permeation Chromatography
Samples dissolved in THF were filtered through a Teflon (PTFE) syringe filter (0.25 μm)
three times. The average molecular weight (Mn) and polydispersity index (PDI = Mw/Mn)
of the polymers were determined by gel permeation chromatography (GPC) against
polystyrene standards using a Shimadzu high performance liquid chromatography
(HPLC) system fitted with PLgel 5 μm MIXED-D columns and SPD-20A ultraviolet−
visible (UV−Vis) detector.
3.6.3. Cell Culture
3.6.3.1. General
Human cervical cancer (HeLa) cells (purchased from ATCC), seeded into a 100 x 20 mm
style sterile tissue culture dish (#353003 BD Falcon, Durham, NC, USA), cultured in
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minimum essential medium (MEM)/Earle’s balanced salt solution (EBSS) (400 μL,
HyClone, SH30024) medium containing 10% fetal bovine serum (FBS) and 100 U/m
penicillin for 24 h under 5% CO2 at 37 °C, and subcultured every 48 hours. pHRhodo
Dextran 10kDa (#P10361 Molecular probes, Life technologies, New York, USA) and
BODIPY-TR

C5

-ceramide-BSA

complex

(#B34400

Molecular

probes,

Life

technologies, New York, USA) were used for endosome and Golgi apparatus staining,
respectively.
3.6.3.2. Microscopic Imaging.
Approximately 10,000 HeLa cells were seeded into a glass-bottomed eight-well chamber
slide (Lab-Tek Thermo Scientific) and cultured in a minimum essential medium
(MEM)/Earle’s balanced salt solution (EBSS) (400 μL) medium containing 10% fetal
bovine serum (FBS) and 100 U/m penicillin for 24 h under 5% CO2 at 37 °C. 80 μL of 20
μM CPNs in water was added to the culture medium directly, and the cells were further
cultured overnight (final CPN concentration: 4 μM). For endosome staining, pHRhodo
Dextran 10kDa (5µM) was incubated for 30 min at 37oC. After washing with fresh
medium, the cells were further incubated for 30 min at 37 °C. A 1 μL aliquot of Hoechst
(5 μg/mL) was added to the culture medium and incubated with the cells for 10 min at 37
°C, and washed two times with phosphate buﬀered saline (PBS). The cells were fixed
with 4% paraformaldehyde for 10 min. Fluorescent images of the cells were obtained
using a DeltaVision Elite Microscope System (Applied Precision, Issaquah, Washington,
USA) equipped with bandpass filters such as blue (410−460 nm, Hoechst), green
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(500−550 nm, CPNs), and red (595-635 nm, Golgi and endosome). Top and bottom of
the chosen cells was identified, and a Z-stack plot was imaged for each channel.
3.6.3.3. Colocalization study
Z-stack microscope images of each sample was obtained as described above.
Colocalization analysis was conducted for three independent cells per polymer and per
organelle (Golgi apparatus and endosome). Colocalization analysis was conducted using
the microscope software (Softworx 5.0 application, Applied Precision, Issaquah,
Washington, USA). Region of interest (ROI) was selected to contain the entire cell.
Pearson’s Correlation Coefficient (PCC) was used to determine colocalization. Negative
control of colocalization was performed by analysis of blue and green channels staining
the nucleus and CPN, respectively. Three independent images of an entire cell were
selected and analyzed to increase the analysis objectivity. Experimental colocalization
PCC values were obtained using the green and red channels staining the CPN and the
target organelle (endosome). One-way ANOVA followed by Tukey means separation
method was conducted for PCC colocalization values between samples of same organelle
using Origin 8 software.
3.7.
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CHAPTER IV

POLYMER BACKBONE DEGRADATION-DEPENDENT
SUBCELLULAR LOCALIZATION
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4.1.

Abstract

Quantitative mitochondria labeling was achieved by endocytosis of biodegradable
conjugated polymer nanoparticle (CPN) followed by the polymer backbone degradation.
The degraded conjugated oligomers (COs) were efficiently trafficked to the target
organelle, while non-degradable CPNs remain mainly in endosomes. The presented
strategy of highly specific intracellular labeling of target organelle will contribute to
increase accuracy of biological imaging and sensing.
4.2.

Introduction

Mitochondrial dysfunction is a key component in various human diseases such as
cancer1, obesity2, diabetes3 and neurodegenerative diseases ranging from Leber’s
hereditary optic neuropathy4 to Alzheimer's disease5. Because the mitochondrion plays a
key role in cell death pathways, targeted drug delivery to this organelle could play a
crucial role for future cancer treatments.6 However, the efficient delivery of therapeutics
into this key organelle has been limited by the highly regulated process required to
achieve mitochondrial internalization.
Successful drug delivery requires permeation through the lipophilic cell membrane,
mitochondrial trafficking, and penetration of the mitochondrial membrane, which results
in a high exclusivity towards a wide variety of molecules. Incorporation of lipophilic
moieties such as triphenylphosphonium (TPP), which contain a delocalized positive
charge, has been reported to facilitate cellular and mitochondrial membrane permeation.7
While direct modification of drugs with TPP, or targeting moieties like it8, has facilitated
internalization into the mitochondria, they are limited to small molecular weight payloads
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and suffer from non-specific cellular adsorption.9 Additionally, the intrinsic diffusion
mechanism requires relatively high probe concentrations, which often lead to nonspecific uptake and toxicity issues.
Polymeric delivery vehicles overcome many of the limitations of direct drug modification
and offer a platform that that can be modified for the intracellular delivery of cargos of
varying charge, size, and molecular weight. Upon appropriate fabrications and surface
modifications, polymer nanoparticles can circulate longer in the blood stream and target
the disease tissues using both passive (i.e., the enhanced permeation and retention effect)
and active (i.e., interaction of ligands specific to the cell surface receptors) targeting
strategies.
Mitochondrial localization of nanocarriers via incorporation of targeting ligands has seen
limited success. For example, mitochondrial localization was observed by incorporation
of TPP onto N-(2-Hydroxypropyl)methacrylamide (HPMA) only in copolymers with an
average molecular weight below 5 kDa. Higher molecular HPMA copolymers did not
show any mitochondrial localization, even after polymer microinjection into the cytosol.
Emerging technologies such as dequalinium, which can form liposome-like aggregates,
have been reported to exhibit plasmid DNA (pDNA) encapsulation, cellular
internalization, and pDNA delivery to the mitochondria. Similar success has been
reported with fusogenic peptides. However, these materials do not exhibit improved
pharmacokinetics, passive or active targeting towards cancer cells.
Here we present a strategy to combine advantages of both small molecules (i.e., high
targeting efficiency) and large polymeric materials (i.e., better cellular entry and in vivo
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properties) to achieve quantitative intracellular organelle labeling. Using the
biodegradability of conjugated polymer nanoparticles (CPNs), almost quantitative
mitochondria labeling was achieved. Upon endocytosis, CPNs were de-assembled and
degraded to low molecular weight, fluorescent mitochondria probes that were efficiently
trafficked to mitochondria. The results support that biodegradable CPNs are promising
labeling and therapeutic delivery materials to mitochondria.
CPNs are fluorescent biomaterials fabricated by self-assembly of non-aqueous solution
conjugated polymers (CPs) in an aqueous solution. Owing to their excellent
photophysical and biophysical properties, have been employed for CPNs have gained
many recent attentions for microscopic cell/tissue imaging,10-13 biological sensing14-19,
and nucleic acid delivery.20-22 Recently, we demonstrated that subtle CPN side-chain and
backbone modifications significantly influence the cellular behaviors including toxicity,
entry mechanism, and subcellular localization.
Herein we report CPN-1 (Figure 4.1), a disulfide linker-containing poly(phenylene
ethynylene) with TPP side-chains exhibiting mitochondria-specific co-localization. To
obtain the fluorescent properties comparable to a fully conjugated PPE, the amount of
disulfide monomer in the PPE backbone was maintained less than 50%. Using a fully
conjugated PPE, CPN-2 was also fabricated to support the concept that the degradability
of CPNs is a crucial part for high intracellular organelle targeting.
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Figure 4.1. Cheemical structu
ures of TPP-co
ontaining PPEss with and witthout biodegraadable linkers in the
baackbone. CPN
N-1 (x:y=3:2) and
a CPN-2 (x:y=1:0) were ffabricated withh the corresponnding PPEs via selfasssembly.

4.3.

Resullts and Discussion

Human
H
cervical carcinom
ma (HeLa) cells
c
were inncubated witth biodegraddable CPN-11 and
non-degradab
ble CPN-2 for
f overnightt, respectiveely. The mettabolic activvity of HeLaa cells
ncubated wiith CPNs was
w measurred by MTT
T assay. C
CPN-1 exhibbits no viaability
in
in
nhibition up
p to 40 µM
M, while CP
PN-2 exhibbits a slightt inhibition (~10% viaability
decrease) (see Supporting Informatio
on). CPNs w
were taken uup by cells and found iin the
cy
ytosolic com
mpartment (Figure 4.2).. Unlike to CPN-2, whhich exhibitss a characteeristic
pu
unctuated paattern, the flu
uorescent paattern of CPN
N-1 was som
mewhat diffuused and graanular
(F
Figure 4.2).
For analyzing
g subcellularr localization
ns of CPNs,, various orgganelles (i.e., nucleus, G
Golgi,
en
ndosome, an
nd mitochon
ndria) were post-stained
p
using comm
mercially available dyes. The
Pearson's Co
orrelation Coefficient
C
(PCC) wass used to quantitativee co-localizzation
ev
valuation. PCC
P
scores of 0 and 1 correspondd to uncorreelated and pperfectly linnearly
co
orrelated colors, respecttively. Mean
n PCC scorees from threee independeent images of an
en
ntire cell were
w
selecteed and anallyzed to inccrease the analysis obj
bjectivity. C
CPN-1

85

ex
xhibited alm
most exclusiive mitocho
ondrial co-loocalization (PCC 0.89)), while minnimal
en
ndosome (0..25) and Gollgi apparatus (0.23) co-llocalizationss were obserrved (Figuree 4.3).
Meanwhile,
M
CPN-2
C
show
wed high en
ndosomal coo-localizationn (PCC 0.776) with minnimal
mitochondria
m
al and Golgi apparatus co-localizatioon (Figure 44.3). Fluoresccence analysis of
th
he mitochon
ndrial fractio
on of Hela cells
c
incubaated with CP
PNs also cleearly supporrt the
qu
uantitative localization of
o CPN-1 in
n mitochonddria. Fluoresccent intensitties at 495 nnm of
mitochondria
m
a and cytosollic fractions, respectivelyy, were com
mpared.

Figure 4.2. Miccroscopic imag
ges of HeLa ceells incubated w
with CPNs. Ceells treated withh CPNs for 188 hours
fo
ollowed by mittochondrial (red
d) and nuclear (blue) stainingg. The scale baar is 20 μm.

This
T
dramatiic subcellulaar localizatiion differennce betweenn CPNs withh the same side
ch
hains (i.e., TPP) impliies that selff-assembly structures oof CPNs poossibly influuence
ceellular entry
y routes and
d the intraccellular fatess. We previously founnd that CPs with
fllexible linkeers tend to form
f
aggreg
gates with hhigh interpollymer interaactions comppared
with
w CPs with
hout the flex
xibility. Becaause of the fl
flexible disullfide bonds, therefore, thhe
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Figure 4.3. Quaantitative co-lo
ocalization anallysis using thee PCC algorithm
m. CPN-1 andd CPN-2 exhibiit high
mitochondria
m
an
nd endosome lo
ocalization, respectively. Thee error bar reppresents ±standdard deviation (n=3).
ANOVA-Tukey
A
y test demonstrrate statisticallly different CP
PN-1 and CPN
N-2 co-localizaation with endosome
an
nd mitochondriia. * p<0.0005.

su
urface propeerties of CPN
N-1 will be different annd influentiall for cellularr interactionns and
su
ubsequent cellular
c
entry
y. To test endocytosis pathways, HeLa cellss pretreated with
ph
harmacologiical inhibito
ors of variou
us endocytossis pathwayss were incubbated with C
CPNs
fo
or 2 hours an
nd mean fluo
orescent inteensity of cellls were moniitored by floow cytometryy.
As
A shown in
n Figure 4.4, CPNs use various enndocytosis pathways to enter HeLaa cell,
determined by
b the reducced uptake of
o CPNs unnder the inhiibitors tested. In additioon to
caaveolae-med
diated endoccytosis (CvM
ME), uptake of CPN-1 vvia macropinocytosis (M
MPC)
allso noticeab
bly reduced
d. Although
h further m
mechanistic and traffickking studiess are
cu
urrently und
derway, we speculate th
hat the highh mitochondrria localizattion of CPN
N-1 is
cllosely related to a series of cellular processes
p
off MPC internnalization off CPN-1,
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Figure 4.4. En
ndocytosis paathways of TP
PP-containing CPNs. Averrage of three independent (n=3)
en
ndocytosis inh
hibition measu
urements of CPNs under pharmacologiical inhibitorss treatments. Mean
flu
uorescent inten
nsity of HeLa cell (Control),, CPNs only (C
CPN), chlorproomazine (24 m
mM, CME), gennistein
(2
210 μM, CvM
ME), methyl-β--cyclodextrin (1000
(
mM, C
CvME/MPC), L
LY294002 (1220 μM, MPC
C), and
cy
ytochalasin D (0.04 mM, MPC)
M
were meeasured using flow cytomettry. Error barss represent staandard
deeviation. *p < 0.05
0 when com
mpared between
n polymers CP
PN-1 and CPN--2.

o disulfide bonds
b
to gen
nerate low m
molecular weeight COs, bbetter escaping of
degradation of
en
ndosomes an
nd macropin
nosomes duee to increaseed hydrophoobicity of CO
Os, and increeased
diffusion to trafficking
t
to
o mitochond
dria. MPC iis known ass a relativelyy non-destruuctive
he macropino
osomes are non-acidic
n
aand leaky.
pathway as th
To
T determinee whether th
he observed
d CPN-1 miitochondrial specificity is related to the
degradation kinetics,
k
wee measured endosome and mitochhondrial co-llocalization as a
unction of time.
t
Subceellular localiization was monitored by fluoresccent microscopic
fu
im
maging, with
h CPNs incu
ubated for 3,
3 6, 12, andd 18 hours in HeLa ceells. PCC sccoring
between CPN
N and mitoch
hondrial or endosomal
e
m
markers was measured annd averaged from
th
hree indepen
ndent trials (Figure 4.5)). CPN-1 exxhibited a time-dependeent mitochonndrial
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and endosomal co-localization. As incubation time increased, CPN-1 localized more
strongly towards the mitochondria, with almost exclusive mitochondrial localization at 18
hours incubation. CPN-2, meanwhile, did not show time-dependent co-localization,
exhibiting no significant change in mitochondrial or endosomal localization as incubation
time increased. Although CPN-2 has high mitochondria targeting TPPs, the nondegradability, large molecular weight, and poor endosome escaping and diffusion
efficiency of CPN-2 limit mitochondria targeting. The time-dependency of CPN-1 on colocalization supports that degradation of biodegradable linkers play a significant role in
mitochondrial trafficking of TPP functionalized COs.
4.4.

Conclusion

We present here a new strategy to achieve a unique time-dependent mitochondrialspecific localization of CPNs. We demonstrated that disulfide-containing CPN exhibits
active cellular internalization as polymer nanoparticles via a variety of endocytosis, and
undergoes degradation to actively trafficking to the mitochondria as low molecular
weight oligomers. The concept we demonstrated here will lead to the development of
novel polymeric materials for improved intracellular targeting and drug delivery
efficiency. Currently, we are performing in vivo studies including pharmacokinetics and
biodistribution, fine-tuning of degradation kinetics, and targeted delivery of drugs to
mitochondria.
4.5.

Outlook

Since the writing of this chapter, a several non-flexible-containing TPP copolymers were
synthesized and screened for mitochondrial-specificity. Preliminary results indicate the
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semi-flexible linker plays a key role in the mitochondrial-specificity exhibited by CPN-1.
Because the key towards the mitochondrial-specificity appears to be the biodegradable
linker, a variety of applications for sensing and delivery emerge by covalent
incorporation of oxygen species (ROS)-sensitive attachment to the CPN. However, the
role that molecular weight play in the mitochondrial-specificity has yet to be explored.
Additionally, whether the CPN localizes on the outer or inner mitochondrial membrane
or mitochondrial lumen, remains to be determined. Successful development of
mitochondria-specific fluorescent label, delivery vehicle, or (ROS) sensors, will depend
on the fate of the CPN. Finally, determination of the precise mechanism by which the
CPN undergoes endosomal escape will facilitate optimization and development of future
CPN polymers. In conclusion, the understanding the role that the semi-flexible linker
plays in the CPN degradation within the cell, and the resulting subcellular distribution,
will continue to facilitate development of novel multifunctional materials for labelling,
sensing, and delivery.
4.6

Experimental Section

Polymer synthesis and characterization was carried out by Dr. Rajesh Kumar Manian.
Toxicity assay was carried out by Yong Myoung.

4.6.1. General Information.
Chemicals, including solvents, were purchased from Fisher Scientific and used as
received. Deuterated solvents were purchased from Cambridge Isotope Laboratories
(Cambridge, MA). UV-vis spectra were recorded using a Varian Cary 50 Bio
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spectrophotometer.

Fluorescence

spectra

were

obtained

using

a

FluoroLog-3

Spectrofluorometer (Jobin Yvon/Horiba). 9, 10-diphenylanthracene (QY = 1.0) in
cyclohexane was used as a fluorescence standard for QY determination. The average
molecular weight (Mn) and polydispersity (PDI = Mw/Mn) of the polymers were
determined by gel permeation chromatography (GPC) against polystyrene standards
using a Shimadzu high performance liquid chromatography (HPLC) system fitted with
PLgel 5 μm MIXED‐D columns and SPD‐20A ultraviolet−visible (UV−vis) detector.
Nuclear magnetic resonance (NMR) spectra were recorded on a 400 MHz Avance Bruker
NMR spectrometer. 1H and

13

C NMR chemical shifts are given in ppm relative to

Si(CH3)4, with the solvent resonance used as internal reference. 1H NMR on the
δ scale based on the middle peak (δ = 2.50 ppm) of the dimethyl sulfoxide DMSO-d6
solvent as an internal standard or 7.26 ppm for chloroform (CDCl3) experiments.

31

P

NMR chemical shifts are reported in ppm relative to H3PO4. The mass spectrometric data
were obtained at the mass spectrometry facility of the Florida International University.
Analytical thin layer chromatography (TLC) was performed on TLC Silica gel 60 F254.
The TLC plates were visualized by shortwave (254 nm) or longwave (360 nm) UV light.
Flash chromatography on silica gel (230–400 mesh) was performed. Fourier transform
infrared (FT-IR) spectrum was obtained on a PerkinElmer Spectrum 100 FT-IR
Spectrometer; fine powder sample was mounted on an attenuated total reflection cell.
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4.6.2. Monomer Synthesis.

Scheme 4.1:
I
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4.6.2.1 Synthesis of monomer 133
1, 4-Dihydroxy-2, 5-diiodobenzene (5.00 g, 13.80 mmol) was dissolved in acetone (20
mL) and the resulting solution was added slowly to a stirred suspension of K2CO3 (7.60
g, 55.25 mmol) and NaI (8.30 g, 55.25 mmol). The reaction mixture was allowed to stir
for 10 min followed by the slow addition of TEG-Cl (5.80 g, 34.53 mmol). The reaction
was heated to 80 ºC for 12 h. The solution was cooled to room temperature, the solvent
was removed, and the resulting slurry was re-dissolved in CH2Cl2 (100 mL). The solution
was extracted with water (100 mL x3) and the organic fractions were collected and
concentrated in vacuo until an oily residue remained. The crude product was purified by
silica gel chromatography (95:5 EA / Hexane). The product was off-white solid. Yield:
5.80 g (67.0%). 1H NMR (400 MHz, CDCl3): δ 7.24 (s, 2H), 4.09- 4.15 (t, 4H), 3.86-3.92
(t, 4H), 3.77-3.82 (m, 4H), 3.69-3.76 (m, 8H), 3.60-3.66 (m, 4H), 2.29 (br, 2H);

13

C

NMR (400 MHz, CDCl3): δ 153.51, 123.21, 86.52, 72.51, 71.22, 70.54, 70.28, 69.66,
61.82.
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4.6.2.2 Synthesis of monomer M134
A suspension of compound 1 (5.00 g, 7.98 mmol) was dissolved in 25 mL of DCM
carbon tetrabromide (8.00 g, 23.95 mmol) and triphenyl phosphine (12.60 g, 23.95 mmol)
added slowly to the reaction mass. The mixture was stirred at room temperature for 2 h.
The solvent was removed and the crude product was purified by column chromatography
(1: 4 EA / Hexane). The product was white solid. Yield: 5.30 g (81.2%). 1H NMR (400
MHz, CDCl3): δ 7.30 (s, 2H), 4.10-4.15 (t, 4H), 3.89-3.92 (t, 4H), 3.85-3.87 (t, 4H), 3.683.76 (m, 4H), 3.60-3.65 (m, 4H), 3.45-3.51 (m, 4H). 13C NMR (400 MHz, CDCl3): δ
153.37, 123.49, 86.47, 71.30, 71.19, 70.71, 70.33, 69.70, 30.42.
Monomer 2 (M2) was synthesized according to literature procedure (Scheme 2)35.
Scheme 4.2
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4.6.2.3 Synthesis of monomer M3.
Scheme 4.3:
O
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3,3'-Dithiodipropionic acid (1.00 g, 4.76 mmol) was dissolved in anhydrous
tetrahydrofuran (20 mL) in a round bottom flask, which was evacuated and filled with
nitrogen. N-methylmorpholine (0.90 g, 9.52 mmol) was added, and the suspension was
allowed to stir until the entire solid was dissolved. Isobutyl chloroformate (1.30 g, 9.52
mmol) was added, and the mixture was allowed to stir at room temperature for 15 min. A
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solution of 4-ethynylaniline (1.10 g, 9.52 mmol) in anhydrous THF (10 mL) was
prepared under a N2 atmosphere and transferred into the reaction flask using a cannula.
The reaction was allowed to proceed overnight, after which the reaction mixture was
filtered. The filtrate was concentrated in vacuo, and the resulting solid was precipitated
overnight from the DCM / diethyl ether solvent system. Yield: 0.70 g (36.0%). 1H NMR
(400 MHz, DMSO): δ 10.20 (s, 2H), 7.50-7.70 (d, 4H), 7.35-7.40 (d, 4H), 4.09 (s, 2H),
2.95-3.10 (t, 4H), 2.62-2.78 (t, 4H).

13

C NMR (400 MHz, DMSO): δ 169.53, 139.68,

132.36, 118.94, 116.12, 83.49, 79.65, 36.08, 33.38. HRMS (ESI): Calcd for C22H20
+
n2O2S2 [M+Na] :

431.0858; found [M+Na]+ : 431.0801.

4.6.3. Polymer Synthesis.
General Procedure. A Schlenk flask was charged with monomer M1 (1.00 eqiv.), M2
(0.5 eqiv.), M3 (0.5 eqiv.) Pd[(PPh3)2Cl2] (0.10 equiv.) and CuI (0.05 equiv.). The
Schlenk flask was evacuated and filled with N2. A solution of anhydrous
dimethylformamide (4 mL) and diisopropylamine (1 mL) was degassed, and 2.5 mL of
the mixed solution was transferred to the Schlenk flask using a cannular needle. The
reaction was allowed to stir at room temperature for 12 h. The solution was then
transferred drop wise to methanol, resulting in precipitation. After centrifugation (3 min,
4000 rpm), the supernatant was decanted, and the precipitate was redissolved in DCM (1
mL) for further purification.
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4.6.3.1 Synthesis of P1.
Scheme 4.4:
I
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P1-Br. Using general procedure described above, the polymerization of monomer M1
(100 mg, 0.133 mmol), M2 (30 mg, 0.066 mmol) and M3 (28 mg, 0.066 mmol) in the
presence of Pd[(PPh3)2Cl2] (9.3 mg, 0.013 mmol), and CuI (1.3 mg, 0.007 mmol).
Resulting mixture was purified by precipitation in methanol (x3) Yield: 105 mg (42.5 %).
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An aliquot was redissolved in THF and molecular weight obtained and photo physical
properties characterized in DCM.
P1-Br: GPC: Mw =13.66 kDa; Mn = 09.30 kDa; PDI = 1.42. UV-vis: λmax = 400 nm; fluo
λmax = 467 nm; QY = 0.69% and ε = 42716.79 M-1 cm-1(Per repeating Unit) in DCM. 1H
NMR (400 MHz, CDCl3): δ 8.25-8.50 (br, 2H), 7.50-7.65 (br, 4H), 7.39-7.52 (br, 4H),
6.90-7.10 (br, 4H), 4.10-4.30 (br, 10H), 3.85-4.00 (br, 11H), 3.70-3.80 (br, 22 H), 3.603.70 (br, 14H), 3.50-3.60 (br, 4H), 3.40-3.50 (br, 5H), 3.30-3.45 (br, 6H), 3.00-3.10 (br,
3H) and 2.75-2.90 (br, 3H). FT-IR (neat): ν = 2924, 2868, 1671, 1589, 1512, 1408, 1352,
1265, 1214, 1097, 1041, 937, 838 cm-1.
4.6.3.2. Synthesis of P1.
Triphenyl phosphine (141 mg, 0.540 mmol) was dissolved in chloroform and resulting
solution was added to a stirred suspension of P1-Br (100 mg, 0.054 mmol). The reaction
was heated to 85 ºC for 12 h. The resulting mixture was purified by precipitation in ethyl
acetate (x5). Yield: 70 mg (44.7%).
P1: UV-vis: λmax = 405 nm; fluo λmax = 472 nm; QY = 0.40% and ε = 67606.65 M-1cm-1
(Per repeating Unit) in DMSO. 1H NMR (400 MHz, CDCl3): δ 7.98-8.10 (br, 2H), 7.407.90 (br, 40H), 7.26-7.45 (br, 4H), 6.80-7.10 (br, 4H), 4.00-4.40 (br, 10H), 3.10-3.90 (br,
65H), and 2.75-3.00 (br, 2H). FT-IR (neat): ν = 2921, 2870, 1683, 1597, 1520, 1430,
1408, 1210, 1099, 1047 cm-1.
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Scheme 4.5:
4.6.3.3 Synthesis of P2.
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P2-Br. Using general procedure described above, the polymerization of monomer M1
(100 mg, 0.133 mmol) and M2 (60.0 mg, 0.133 mmol) in the presence of Pd[(PPh3)2Cl2]
(9.3 mg, 0.013 mmol), and CuI (1.3 mg, 0.007 mmol). Resulting mixture was purified by
precipitation in methanol (x3) Yield: 0.15 g (88.5 %). An aliquot was redissolved in THF
and molecular weight obtained and photo physical properties characterized in DCM.
P2-Br: GPC: Mw = 26.36 kDa; Mn = 15.98 kDa; PDI = 1.65. UV-vis: λmax = 432 nm; fluo
λmax = 473 nm; QY = 0.53% and ε = 23526.82 M-1 cm-1(Per repeating Unit) in DCM. 1H
NMR (400 MHz, CDCl3): δ 7.05-7.10 (br, 4H), 4.25-4.30 (br, 8H), 3.87-3.95 (br, 9H),
3.75-3.80 (br, 12H), 3.59-3.65 (br, 13H), 3.45-3.52 (br, 4H), 3.42-3.48 (4H), 3.35-3.38
(br, 7H). FT-IR (neat): ν = 2923, 2870, 2197, 1510, 1423, 1270, 1241, 1092, 1060 cm-1.
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4.6.3.4. Synthesis of P2.
Triphenyl phosphine (270 mg, 1.02 mmol) was dissolved in chloroform and resulting
solution was added to a stirred suspension of P2-Br (100 mg, 0.102 mmol). The reaction
was heated to 85 ºC for 12 h. The resulting mixture was purified by precipitation in ethyl
acetate (x5). Yield: 95 mg (61.7%).
P2: UV-vis: λmax = 436 nm; fluo λmax = 478 nm; QY = 0.25% and ε = 46128.66 M-1 cm1

(Per repeating Unit) in DMSO. 1H NMR (400 MHz, DMSO): δ 7.56-7.90 (br, 32H),

7.02-7.12 (br, 4H), 6.98-7.00 (br, 1H), 4.15-4.30 (br, 8H), 3.80-3.95 (br, 4H), 3.72-3.79
(br, 6H), 3.50-3.60 (br, 15H), 3.34-3.50 (br, 14H), 3.35-3.40 (br, 4H), 3.10-3.20 (br, 9H).
FT-IR (neat): ν = 3393, 2874, 2190, 1625, 1493, 1437, 1420, 1353, 1207, 1102, 1046 cm1

.

4.6.4. Determination of zeta potentials of P1 and P2.
Dynamic light scattering measurements were performed by Zetasizer nano-ZS (Zen
3600, Malvern Instruments Ltd.) using a folded capillary cell (Catalog # DTS1060), at
room temperature. The samples were prepared at approximately 0.1 mM in a 5% DMSO
(v/v) solution using deionized water (18 Ω), which was filtered through 0.45 μm PTFE
syringe filter. Each sample was measured six times.
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Figure 4.5. Zeta potential of P1

Figure 4.6. Zeta potential of P2
4.6.5 Toxicity Assay.
HeLa cells (ca. 10 000 cells per well) in 200 μL of complete medium were seeded into a
96-well plate and cultured for one day in a 5% CO2 incubator at 37 °C. CPNs with
various concentrations (1 to 40 μM) were added and incubated for 24 h. To measure
toxicity, 10 μL of MTT solution (5 mg mL-1 in PBS) and 90 μL of complete medium
were then added into each well, and the plate was further incubated for 4 h at 37 °C. After
formed MTT formazan crystals were dissolved in dimethyl sulfoxide (100 μL), the
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similar manner for absorption and emission measurements using 10% methanol (v/v) in
water (18 Ω) filtered through 0.45 μm polytetrafluoroethylene (PTFE) syringe filters. The
samples were injected into the sample chamber with 1 mL sterile syringes (Restek
Corporation, Pennsylvania, USA) until the liquid reached the tip of the nozzle. All
measurements were performed at 25°C using a LM14C temperature controller
(NanoSight, Amesbury, United Kingdom). Each sample was measured three times.
4.6.7 Cell Culture.
General.
HeLa cells (human cervical cancer, purchased from ATCC), seeded into a 100 x 20 mm
style sterile tissue culture dish (#353003 BD Falcon, Durham, NC, USA), cultured in
minimum essential medium (MEM)/Earle’s balanced salt solution (EBSS) (400 μL,
HyClone, SH30024) medium containing 10% fetal bovine serum (FBS) and 100 U/m
penicillin for 24 h under 5% CO2 at 37 °C, and subcultured every 48 hours. pHRhodo
Dextran 10kDa (#P10361 Molecular probes, Life technologies, New York, USA) and
BODIPY-TR

C5

-ceramide-BSA

complex

(#B34400

Molecular

probes,

Life

technologies, New York, USA) were used for endosome and Golgi apparatus staining,
respectively.
4.6.8 Microscopic Imaging.
10,000 HeLa cells were seeded into a glass-bottomed eight-well chamber slide (Lab-Tek
Thermo Scientific) and cultured in a minimum essential medium (MEM)/Earle’s
balanced salt solution (EBSS) (400 μL) medium containing 10% fetal bovine serum
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(FBS) and 100 U/m penicillin for 24 h under 5% CO2 at 37 °C. 80 μL of 20 μM CPNs in
water was added to the culture medium directly, and the cells were further cultured
overnight (final CPN concentration: 4 μM). For endosome staining, pHRhodo Dextran
10kDa (5µM) was incubated for 30 min at 37oC. For Golgi apparatus staining, BODIPYTR C5 -ceramide-BSA complex (final 10 μM) was incubated for 30 min at 4 °C. After
washing with fresh medium, the cells were further incubated for 30 min at 37 °C. A 1 μL
aliquot of Hoechst (5 μg/mL) was added to the culture medium and incubated with the
cells for 10 min at 37 °C, and washed two times with phosphate buﬀered saline (PBS).
The cells were fixed with 4% paraformaldehyde for 10 min. Fluorescent images of the
cells were obtained using a DeltaVision Elite Microscope System (Applied Precision,
Issaquah, Washington, USA) equipped with bandpass filters such as blue (410−460 nm,
Hoechst), green (500−550 nm, CPNs), and red (595-635 nm, Golgi and endosome). Top
and bottom of the chosen cells was identified, and a Z-stack plot was imaged for each
channel.
4.6.9. Colocalization study.
Z-stack microscope images of each sample was obtained as described above.
Colocalization analysis was conducted for three independent cells per polymer and per
organelle (Golgi apparatus and endosome). Colocalization analysis was conducted using
the microscope software (Softworx 5.0 application, Applied Precision, Issaquah,
Washington, USA). Region of interest (ROI) was selected to contain all of the cell.
Pearsons Correlation Coefficient (PCC) was used to determine colocalization. Negative
control of colocalization was performed by analysis of blue and green channels staining
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the nucleus and CPN, respectively. Three independent images of an entire cell were
selected and analysed to increase the analysis objectivity.
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CHAPTER V

CONTROLLED INCORPORATION OF
HOMO-COUPLED BENZOTHIADIAZOLE TO THE
CONJUGATED BACKBONE
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5.1

Abstract

We successfully controlled the incorporation of homo-coupled benzothiadiazole(HBT)
blocks onto the conjugated polymer nanoparticle (CPN). This was achieved by
employing competing polymerization conditions between the cross (i.e., Sonogashira)
and homo-coupling reactions. Using these conditions we were able to synthesize a suite
of polymers such as BT-containing poly-parapheneylene ethynelene (BTPEs), HBTcontaining PPE (HBT-PE), and BTPE-containing poly-parapheneylene butadiyene
(BTPE-PPB), exhibiting a range of emissions. This advancement can result in the
synthesis of new and exciting red-emissive polymers for tissue labeling and cellular
sensing.
5.2.

Introduction

Conjugated polymer nanoparticles (CPNs) are promising fluorescent biomaterials
exhibiting high brightness and efficient energy transfer making them suitable for cellular
labelling and sensing applications.1 Various chemosensors have been reported that take
advantage of the unique signal amplification or superquenching as the fluorescent CPN
interacts with analytes of interest.2 Because of their conjugated nature, any interaction
occurring along the polymeric backbone will result in the perturbation of the electron
transport properties of the conjugated system affects the entire assembly. Additionally,
CPNs exhibit aggregation based absorbance and emission changes, making CPN-based
molecular probes sensitive even minor perturbations upon analyte-polymer interactions
and binding.3 Therefore, a multitude of analyte-CPN interactions will result in large
signal amplification due to the collective features of the CP. 4
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For biological applications, synthesis of CPs exhibiting red emission is highly desirable
as the sensitivity of any in vivo measurements and optical imaging is enhanced due to
minimal autofluorescence from biological tissues at this range CPs that have incorporated
electron donating and accepting moieties onto the conjugated backbone have been shown
to effectively modulate the CP’s electronic properties resulting in red shifted emissions.5
As an electron-accepting moiety, 2,1,3-Benzothiadiazole (BT) has been used in various
oligomers and polymers, exhibiting orange to red emission, with higher incorporation of
the BT units into the CP backbone improving absorption, thermal stability,
electrochemical and charge transport properties of the resulting copolymers.6 Among
BT-containing CPs, materials containing homo-coupled benzothiadiazole (HBT)
segments in the conjugated backbone have been shown to further improve the materials
optical and electronic properties.7 Despite these favorable properties, there have been few
reports on the use of HBT-containing materials due to a lack of an efficient method for
their synthesis. Most reports of HBT synthesize include time- and step-intensive methods
involving the synthesis of 7,7'-dibromo-4,4'-bibenzo[c][1,2,5]thiadiazole which is then
polymerized.8-9 However, copper-catalyzed oxidative addition under strong basic
conditions has also been reported for HBT synthesis.10
Recently, we reported the synthesis of flexible poly(p-phenylenebutadiynylene)s (PPBs)
using competing Sonogashira and Glaser coupling conditions, and taking advantage of
the differences in monomer reactivity to incorporate a small amount (~10%) of flexible,
non-conjugated linkers into the backbone.11 The reaction conditions provide limited
control over the proportion of flexible monomer incorporation, effectively affording
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phenylene-ethynylene(PE)-doped PPBs. We hypothesized that by using competing
Sonogashira and benzothiadiazole homo-coupling conditions, we could easily synthesize
HBT-containing PPEs.
Here we report a one-pot method for the controlled incorporation of HBT blocks onto the
CP backbone. Using commercially available BT monomers, we were able to synthesize
HBT-containing CPs without employing the time- and step-intensive methods usually
employed to afford these polymers. Using this one-pot method, we successfully
synthesized a suite of polymers such as BT-containing poly-parapheneylene ethynelene
(BTPEs), HBT-containing PPE (HBT-PE), and BTPE-containing poly-parapheneylene
butadiyene (BTPE-PPB), exhibiting a range of emissions.
5.3.

Results and Discussion

It was hypothesized that high copper content and increased base strength would facilitate
HBT incorporation during the polymerization process. This is because HBT synthesis has
been reported via copper-catalyzed oxidative addition under strong basic conditions, the
modified coupling conditions. To create a competing environment between the cross (i.e.,
Sonogashira) and homo-coupling of the monomers, varying amounts of copper (5% or
95% molar equivalents) catalyst and organic bases of increasing base strength
(TEA>morpholine>Pyridine>K2CO3) were employed. The reactions were carried out in a
nitrogen environment at 60°C in overnight using dimethylformamide as the
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Scheme 5.1. Synthesis of HBT-BTPE and BTPE polymers

Table 5.1. . List of polymer chemical structures at various reaction conditions
Polymer

CuI

Pd(II)

Base

xa

ya

P1

5%

5%

TEA

0

1

P2

5%

5%

Morpholine

0.12

1

P3

5%

5%

Pyridine

0.4

1

P4

5%

5%

K2CO3

0.7

1

P5

95%

5%

TEA

0.4

1

P6

95%

5%

Morpholine

0.8

1

P7

95%

5%

Pyridine

1.4

1

P8

95%

5%

K2CO3

2.4

1

P9

2eq

5%

K2CO3

2.4

1

a

Determined by 1H NMR peak integration.

polymerization solvent, as outlined in Scheme 5.1. A series of polymers were prepared
under these modified palladium/copper/base conditions as listed in Table 5.1.
The chemical structure of the resulting polymers was assessed by 1H NMR spectroscopy.
An example of the quantitative assessment of the presence HBT segments is illustrated
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on the structure of polymer P4 (Figure 5.1). The 1H NMR spectrum clearly exhibits three
distinct aromatic peaks at 7.95, 7.30, and 6.74 ppm corresponding to HBT, BT, and PE
aromatic peaks, respectively. 2-dimensional NMR confirms that peak the peaks at 7.95
and 7.30 ppm are both from a BT moiety. The integration ratio between the HBT
(7.95ppm) and PE (6.74ppm) peaks indicates that the incorporation of the HBT-segments
to the conjugated backbone was approximate 66%. Figure 5.2 demonstrated the
increasing incorporation of HBT onto the conjugated backbone as demonstrated by the
increasing size of the HBT aromatic peak increases as a function of base strength and
copper catalyst loading. Full NMR spectra for all polymers are included in the
Experimental Section.

Figure 5.1. 1H-NMR for polymer P4 in DMSO-d6
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Figurre 5.2. 1H-NMR aromatic reggions for polym
mer P1-P8

Although
A
inccreased copp
per catalystt conditionss will heaviily favor foormation of PPB
seegments onto the conjug
gated backbo
one, no suchh incorporatioon was obseerved for pollymer
P1-P8.
P
An in
ntegration raatio of greateer than 1 beetween BT (7.30ppm) annd PE (6.744ppm)
peaks would signal formaation of PPB
B segments. We hypotheesize that thee activated nnature
of the BT mo
onomer enhaances BT-PE
E formation, thereby reduucing PPB fformation. To test
th
his hypothessis, two more polymerss, P10 and P11, were synthesized under increeased
palladium and copper caatalyst to faccilitate PPB formation. We expecteed enhancedd PPB
nder these conditions given
g
that Glaser-coupl
G
ling is the result of paalladium-asssisted
un
co
opper cataly
ysis, and BT--homocoupliing the resullt of increaseed copper annd base.13-14
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Figure 5.3.. A) Absorbancce and B) emisssion spectra foor selected polyymers. As HB
BT incorporatioon
in
ncreases, materrials experiencce absorbance and
a emission reed-shifts. P111 (BTPE-PPB),, containing noo HBT
segments shows
s
most blu
ue shifted absoorbance and em
mission profiless.

In
ndeed, underr these cond
ditions, PPB
B formation w
was observeed; spectra aand details aare in
th
he experimen
ntal section.
The
T absorptio
on and emiission spectrra of BTPE
E and HBT were also representativve of
in
ncreased BT
T incorporattion. As BT
T incorporatiion increaseed, polymerr absorbancee and
em
mission waas further reed shifted. Similarly, control pollymers suchh as PPB-B
BTPE
co
opolymer P11, exhibiteed the expeccted blue shhift due to the lack off HBT segm
ments.
Selected abso
orbance and emission speectra are higghlighted in ffigure 5.3.
Because
B
the stoichiometr
s
ric balance needed
n
for S
Sonogashira coupling is broken as H
HBTin
ncorporation
n increases, the resultin
ng moleculaar weights and yields are expecteed to
decrease. Mo
olecular weiights, solubiility, and reeaction yieldds were connsistent withh the
brreaking of stoichiometr
s
ric balance, physical prooperties of ppolymers P11-P8 are listted in
taable 5.2.
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Table 5.2. Physical and optical properties

a

Polymer

Yield (%)

Mn
(kDa)a

PDIb

P1

65

13.5

1.69

P2

71

10.3

1.95

497

595

P3

40

12.4

1.76

502

633

P4

48

12.7

1.75 494,553 620

P5

67

14.5

1.89 500,551 621

P6

54

8.52

1.92

551

640

P7

62

14.5

1.89

553

646

P8

57

8.52

1.92

552

651

Em
Abs
λmax λmax
(nm)c (nm)e
454
571

Determined by gel permeation chromatography in THF. b PDI (polydispersity index) = Mw/Mn. cMeasured
in ACN. d P1,P2, P3 excitation wavelength 450 nm, P4-P8 excitation wavelength 500 nm in ACN.

5.4.

Conclusion

In conclusion, by creating a competing environment between the cross (i.e., Sonogashira)
and homo-coupling of the monomers, we were able to synthesize HBT-containing CPs
without employing the time- and step-intensive methods usually employed to afford these
polymers. Additionally, we successfully synthesized a suite of polymers such as BTcontaining poly-parapheneylene ethynelene (BTPEs), HBT-containing PPE (HBT-PE),
and BTPE-containing poly-parapheneylene butadiyene (BTPE-PPB), exhibiting a range
of emissions. This advancement can result in the synthesis of new and exciting redemissive polymers for tissue labeling and cellular sensing.
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5.5.

Outlo
ook

c
bisb
benzothiadiaazole (BBT) monomer w
was synthesizzed to
Since the writing of this chapter,
onfirm the id
dentity of th
he BBT moieety being geenerated in situ and incorporated ontto the
co
co
onjugated backbone.
b
Th
he monomeer was then used to geenerate a bissbenzothidiaazoleph
henylene etthynylene copolymer, exhibiting
e
tthe 7.95 annd 6.73 ppm
m peaks for the
ch
haracteristic BBT and PE
E aromatic protons,
p
resppesctively, seee Figure 5.44.

Figure 5.4. 1H-N
NMR for polym
mer BBT-contaaining polymerr in DMSO-d6

In
nspired by th
he recent wo
orks by Maissonneuve15 aand Bunz16, polymer P88 was screenned as
a molecular sensor for the analytical detectioon of enviroonmentally and biologiically
reelevant metaal ions; the polymer exhibited rem
markable quuenching sennsitivity tow
wards
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molecular tin (Sn). Interestingly, as HBT-incorporation increased, tin sensitivity
exponentially increased, with polymers P7 and P8 exhibiting low nanomolar and high
picomolar sensitivity, respectively. Among the different metal ions, tin, has been
established to be an essential trace element for some animals. Although tin is not easily
absorbed by animals and humans, tin deficiency has been linked with poor growth,
hearing loss, and increased cancer risk. Acute tin toxicity has been shown to affect iron
and copper metabolism by interfering with heme and cytochrome P450. Because the role
tin plays in biochemical processes at the cellular level remains largely unknown, there is
great importance is attached to developing sensitive tin-specific chemosensors. In recent
years, significant emphasis has been placed on the development of new, highly selective
fluorescent chemosensors of different architectures for metal cations because of their
potential applications in biochemistry and environmental research. Owing to their
excellent photophysical and biophysical properties, CPNs are rapidly emerging as an
exciting fluorescent platform for sensitive biological sensing.
5.5. Experimental Section
5.5.1. General Data. Chemicals, including solvents, were purchased from Fisher

Scientific and used as received. Deuterated solvents were purchased from Cambridge
Isotope Laboratories (Cambridge,MA). UV−vis spectra were recorded using a Varian
Cary 50 Bio spectrophotometer. Fluorescence spectra were obtained using a FluoroLog-3
Spectrofluorometer (Jobin Yvon/ Horiba). 9,10-diphenylanthracene (QY = 1.0) in
cyclohexane was used as a fluorescence standard for QY determination. The average
molecular weight (Mn) and polydispersity index (PDI = Mw/Mn) of the polymers were
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determined by gel permeation chromatography (GPC) against polystyrene standards
using a Shimadzu high performance liquid chromatography (HPLC) system fitted with
PLgel 5 μm MIXED-D columns and SPD-20A ultraviolet− visible (UV−vis) detector.
Nuclear magnetic resonance (NMR) spectra were recorded on a 400 MHz and 600 MHz
Avance Bruker NMR spectrometer. Chemical shifts were reported in parts per million
(ppm) for 1H-NMR on the δ scale based on the middle peak (δ = 2.50 ppm) of the
dimethyl sulfoxide (DMSO)-d6 solvent as an internal standard. Solutions of Tables and
graphs were plotted using Origin 8 software (OriginLab, Northampton, MA, USA).
5.5.2 Polymer Synthesis.

General Procedure. A Schlenk flask was charged with aryl halide monomer A (1.0 eqiv)
and diactylene monomer B (1.0 equiv), along with Pd[(PPh3)2Cl2] (0.1 equiv) and CuI
(0.05 or 0.95 equiv). The Schlenk flask was evacuated and filled with N2 three times. A
solution of anhydrous dimethylformamide (DMF) (4 mL) and freshly distilled
trimethylamine (1 mL) was degassed, and 1 mL of the mixed solution was transferred to
the Schlenk flask using a cannular needle. The reaction was heated at 70 °C for14 h. The
solution was then cooled to room temperature and transferred dropwise to cold methanol,
resulting in precipitation. After centrifugation (2 min, 4000 rpm), the supernatant was
decanted, and the precipitate was redissolved in DCM(1 mL) for and precipitated two
more times for purification. The resulting precipitate was then dried under high vacuum
for 2 days, weighed and characterized.
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Scheme 5.2. Generalized scheme for BTPE-PPB formation

Table 5.3. Chemical properties of P8, P10, and P11

Polymer

CuI

Pd(II)

Base

x

y

z

P8

95%

5%

K2CO3

1.2

1

0

P10

95%

10%

K2CO3

0.15

1

0.45

P11

95%

20%

K2CO3

0

1

2.1

Table 5.4. Physical and optical properties of P8, P10, and P11

Polymer CuI Pd(II)

Base

Yield
(%)

Mn
(kDa)

PDI

Abs
Em
λmax λmax
(nm) (nm)

P9

2eq

5%

K2CO3

37

13.5

1.97

671

5.0

P10

95%

10%

K2CO3

71

10.3

1.95 420,500 608

5.5

P11

95%

20%

K2CO3

40

12.4

1.76

400

525

3.6

Mod

5%

5%

K2CO3

41

9.87

1.81

500

622

3.1
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QY

P1. Using the general procedure described above, the polymerization of monomer 9 (32
mg, 0.044 mmol) and monomer 13 (20 mg, 0.044 mmol) in the presence of
Pd[(PPh3)2Cl2] (3 mg, 0.0044 mmol) and CuI (0.2 mg, 0.0022 mmol) yielded PPE
polymer P-1 ( 32 mg, 71%). Molecular weight of boc-protected polymer was obtained
and characterized. Resulting mixture was purified by precipitation in cold ethyl ether
(x3). An aliquot was redissolved in THF and molecular weight obtained and photophycal
properties characterized. The rest of the material was dissolved in DMSO-d6 and
characterized using 1H-NMR.
P1: GPC: Mw =22.82 kDa; Mn= 13.5 kDa; PDI = 1.69. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.31 (br, 1H, Bt-H), 6.74
(br, 1H, Ph-H), 4.27 (br, 2H CH2OPh), 3.83 (br, 2H, OCH2), 3.56 (br, 2H, CH2O), 3.09
(br, 2H, OCH2), 1.33 (s, 7H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w), 2935
(m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m), 1363
(s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m).
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Figure 5.5. 1H-NMR for polymer P1 in DMSO-d6

P2. Using the general procedure described above, the polymerization of 6 (30 mg, 0.056
mmol) and monomer M2 (41 mg, 0.056 mmol) in the presence of Pd[(PPh3)2Cl2] (4 mg,
0.0056 mmol) and CuI (0.3 mg, 0.0028 mmol) yielded PPE polymer P2 ( 44 mg, 73%).
Resulting mixture was purified by precipitation in cold ethyl ether (x3). An aliquot was
redissolved in THF and molecular weight obtained and photophycal properties
characterized. The rest of the material was dissolved in DMSO-d6 and characterized
using 1H-NMR. CPN formation was then carried out as described in general procedure to
yield CPN-2
P2: GPC: Mw =20.09 kDa; Mn= 10.3 kDa; PDI = 1.95. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (br, 0.12H, HBt-H),
7.29 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.27 (br, 2H CH2OPh), 3.85 (br, 2H, OCH2),
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3.09 (br, 2H, OCH2), 1.32 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w),
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m),
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m).

Figure 5.6. 1H-NMR for polymer P2 in DMSO-d6

P3. Using the general procedure described above, the polymerization of monomer 4 (65
mg, 0.054 mmol) and monomer 13 (32 mg, 0.054 mmol) in the presence of
Pd[(PPh3)2Cl2] (8 mg, 0.0054 mmol) and CuI (0.4 mg, 0.0022 mmol) yielded PPE
polymer P3 ( 45 mg, 61%). Resulting mixture was purified by precipitation in cold ether
(x3). An aliquot was redissolved in THF and molecular weight obtained and photophycal
properties characterized. The rest of the material was dissolved in DMSO-d6 and
characterized using 1H-NMR.
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P3: GPC: Mw =21.82 kDa; Mn= 12.4 kDa; PDI = 1.76. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 0.37H, HBt-H),
7.30 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2),
3.11 (br, 3H, OCH2), 1.33 (s, 10H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w),
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m),
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m).

Figure 5.7. 1H-NMR for polymer P3 in DMSO-d6

P4: GPC: Mw =22.23 kDa; Mn= 12.7 kDa; PDI = 1.75. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 0.6H, HBt-H),
7.30 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2),
3.12 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w),
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2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m),
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m).

Figure 5.8. 1H-NMR for polymer P4 in DMSO-d6

P5: GPC: Mw =27.41 kDa; Mn= 14.5 kDa; PDI = 1.89. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 2.3H, HBt-H),
7.30 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2),
3.12 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w),
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m),
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m).
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Figure 5.9. 1H-NMR for polymer P5 in DMSO-d6

P6: GPC: Mw =16.36 kDa; Mn= 8.52 kDa; PDI = 1.92. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 0.7H, HBt-H),
7.30 (br, 1H, Bt-H), 6.75 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2),
3.13 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w),
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m),
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m).
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Figure 5.10. 1H-NMR for polymer P6 in DMSO-d6

P7: GPC: Mw =27.41 kDa; Mn= 14.5 kDa; PDI = 1.89. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 0.7H, HBt-H),
7.30 (br, 1H, Bt-H), 6.75 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2),
CH2O), 3.13 (br, 2H, OCH2), 1.33 (s, 7H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982
(w), 2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393
(m), 1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m).
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Figure 5.11. 1H-NMR for polymer P7 in DMSO-d6

P8: GPC: Mw =14.7 kDa; Mn= 7.75 kDa; PDI = 1.90. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 2.3H, HBt-H),
7.30 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2),
3.12 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w),
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m),
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m).
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Figure 5.12. 1H-NMR for polymer P8 in DMSO-d6

P9: GPC: Mw =13.49 kDa; Mn= 6.85 kDa; PDI = 1.97. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 2.3H, HBt-H),
7.30 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2),
3.12 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w),
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m),
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m).
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Figure 5.13. 1H-NMR for polymer P9 in DMSO-d6

P10: GPC: Mw =24.43 kDa; Mn= 16.4 kDa; PDI = 1.49. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.96 (t, 0.3H, HBt-H),
7.31 (br, 0.7H, Bt-H), 6.74 (br, 1H, Ph-H), 4.26 (br, 2H CH2OPh), 3.84 (br, 2H, OCH2),
3.48 (br, 2H, CH2O), 3.07 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν =
3372 (br), 2982 (w), 2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m),
1425 (m), 1393 (m), 1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033
(m).
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Figure 5.14. 1H-NMR for polymer P10 in DMSO-d6

P11: GPC: Mw =24.43 kDa; Mn= 16.4 kDa; PDI = 1.49. UV λmax = 427 nm; fluo λmax(400
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.30 (br, 0.3H, Bt-H),
6.74 (br, 1H, Ph-H), 4.27 (br, 2H CH2OPh), 3.83 (br, 2H, OCH2), 3.56 (br, 2H, CH2O),
3.09 (br, 2H, OCH2), 1.33 (s, 9H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w),
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m),
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m).
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Figure 5.15. 1H-NMR for polymer P11 in DMSO-d6

Polymer Characterization. Confirmed using 1H-NMR data by looking at characteristic
aromatic peak for homo-coupled benzothiadizole (7.97ppm), phenylene ethynylenecoupled benzothiaidzole (7.31), and phenylene (6.74) protons. IR samples were prepared
by lyophilization to prepare neat sample. IR scans from 4000 to 700 cm-1 are presented
below, depicting absence of boc-carbonate group and confirming deprotection.
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